Brain dysfunction and cell death in type 2 diabetes : A neuroprotective role for the peripheral treatment with Exendin-4 by Sebastião, Inês Carolina de Sousa Madeira e Antunes
1 
 
In
ê
s 
S
e
b
a
st
iã
o
 
B
ra
in
 D
y
sf
u
n
ct
io
n
 a
n
d
 C
el
l 
D
ea
th
 i
n
 T
y
p
e 
2
 D
ia
b
et
es
: 
A
 n
eu
ro
p
ro
te
ct
iv
e 
ro
le
 f
o
r 
th
e 
p
er
ip
h
er
al
 t
re
at
m
en
t 
w
it
h
 E
x
en
d
in
-4
 
 
 
 
 
 
 
 
2014 DEPARTAMENTO DE CIÊNCIAS DA VIDA 
 
FACULDADE DE CIÊNCIAS E TECNOLOGIA 
UNIVERSIDADE DE COIMBRA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brain Dysfunction and Cell Death in Type 
2 Diabetes: 
A neuroprotective role for the peripheral 
treatment with Exendin-4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inês Carolina de Sousa Madeira e 
Antunes Sebastião 
 
 
2014 
 

2 
 
 
 
 
 
 
 
DEPARTAMENTO DE CIÊNCIAS DA VIDA 
 
FACULDADE DE CIÊNCIAS E TECNOLOGIA 
UNIVERSIDADE DE COIMBRA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brain Dysfunction and Cell Death in Type 2 Diabetes: 
A neuroprotective role for the peripheral treatment with 
Exendin-4 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertação apresentada à Universidade de 
Coimbra para cumprimento dos requisitos 
necessários à obtenção do grau de Mestre 
em Bioquímica, realizada sob a orientação 
científica da Doutora Ana Isabel Duarte 
(Universidade de Coimbra) 
 
 
 
 
 
 
 
Inês Carolina de Sousa Madeira e Antunes Sebastião 
 
 
    2014 
  
 

3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Esta cópia da tese é fornecida na condição de que quem a consulta reconhece que os direitos de autor são 
pertença do autor da tese e que nenhuma citação ou informação obtida a partir dela pode ser publicada sem a 
referência apropriada. 
 
This copy of the thesis has been supplied on the condition that anyone who consults it understands that its 
copyright belongs to the author and that neither quotation nor information from the thesis can be published 
without proper acknowledgement. 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It always seems impossible until it’s done. 
   Nelson Mandela 
 
 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
AGRADECIMENTOS 
 
Chegado o final desta longa e enriquecedora etapa, resta-me agradecer a todos aqueles que fizeram parte 
deste percurso, tornaram possível a sua concretização e de alguma forma me ajudaram a cumprir este objectivo. 
 
Esta Dissertação de Mestrado em Bioquímica da Faculdade de Ciências e Tecnologia da Universidade 
de Coimbra resulta de um trabalho concretizado com o apoio concedido pelo Centro de Neurociências e 
Biologia Celular, Instituto para Investigação Interdisciplinar da Universidade de Coimbra e Departamento de 
Ciências da Vida da Faculdade de Ciências e Tecnologia da Universidade de Coimbra, os quais forneceram 
importantes meios materiais e humanos, indispensáveis para a realização deste trabalho experimental e para a 
elaboração desta Dissertação. 
 
Ao Programa Operacional Factores de Competitividade - COMPETE e fundos Portugueses via 
Fundação para a Ciência e a Tecnologia (FCT), através dos Projectos PTDC/SAU-NMC/110990/2009, 
PTDC/SAU-TOX/117481/2010 e Pest/SAU/LA0001/2011), que forneceram uma preciosa ajuda monetária, 
essencial para a aquisição de muitos dos materiais necessários para a execução do trabalho experimental. 
 
À Doutora Ana Isabel Duarte, Orientadora deste projecto, e um exemplo de dedicação e empenho, 
agradeço profundamente todos os ensinamentos transmitidos e o tempo que me disponibilizou, assim como as 
suas correções e vasta orientação científica que foram uma valiosa contribuição na realização desta dissertação. 
Além de tudo o acima mencionado, agradeço verdadeiramente a confiança que sempre depositou em mim, o seu 
constante incentivo e palavras de motivação, e as propostas de novos desafios, agentes sempre presentes em 
todos os momentos em que tive o prazer e o privilégio de com ela interagir. 
Ao Professor Doutor António Moreno, Orientador Interno desta Dissertação, agradeço ter aceitado ser 
meu orientador interno, assim como o seu apoio, atenção, interesse e disponibilidade demonstrada ao longo 
deste período. 
À Professora Doutora Paula Isabel Moreira, co-mentora deste projecto, agradeço por me ter recebido no 
seu laboratório e pela confiança que depositou em mim, assim como a sua orientação e o precioso apoio ao 
longo do desenvolvimento experimental deste trabalho, os quais foram pontos essenciais para a conclusão do 
mesmo. Um muito obrigado pela sua partilha de conhecimentos científicos e disponibilidade demonstrada ao 
longo de todo o período de desenvolvimento deste projecto.  
 
À Doutora Maria Sancha de Jesus Vieira dos Santos agradeço o apoio, ajuda laboratorial e 
disponibilidade prestados no decorrer do trabalho experimental deste projecto. 
 
À Professora Doutora Catarina Isabel Neno Resende de Oliveira estou grata pela oportunidade de redigir 
um artigo revisão e pela confiança depositada em mim, assim como o apoio, disponibilidade e conselhos 
científicos.   
 
Aos membros do grupo de trabalho da Professora Doutora Paula Moreira, são eles a Ana Plácido, a 
Cristina, a Sónia, a Susana, o Renato e o Rui agradeço profundamente toda a ajuda e o apoio prestados ao longo 
deste período, assim como a transmissão de conhecimentos teóricos e técnicas laboratoriais que se mostraram 
cruciais na elaboração deste trabalho. Agradeço em especial ao Emanuel pela sua paciência e imensa ajuda e 
apoio que me deu ao longo deste ano na execução do trabalho laboratorial, além dos muitos momentos de 
camaradagem, amizade e sempre muito boa disposição. Aos acima mencionados e aos membros do grupo da 
Professora Doutora Sandra Cardoso, a Diana e a Raquel, agradeço também a simpatia, os muitos momentos de 
convivência e as horas de almoço recheadas de bom humor. Também aos membros da Doutora Cláudia Pereira, 
à Rosa e à Catarina, agradeço a simpatia e a disponibilidade que mostraram comigo. 
 
A todos os membros do Grupo “Metabolismo Celular & Controlo de Qualidade” agradeço o entusiasmo 
e rigor científico, a ajuda prestada ao longo do meu trabalho, os importantes conselhos e partilha de 
conhecimentos científicos que foram pontos essenciais para a preparação do meu trabalho laboratorial e na 
 
8 
 
minha educação científica.   
 
Aos funcionários e técnicos do Centro de Neurociências e Biologia Celular e do Departamento de 
Ciências da Vida agradeço toda a simpatia e apoio que me prestaram ao longo deste ano.  
 
Gostaria ainda de agradecer aos funcionários e técnicos do Biotério do Centro de Neurociências e 
Biologia Celular e Faculdade de Medicina da Universidade de Coimbra a preciosa colaboração prestada na 
manutenção dos animais utilizados neste projecto de investigação. 
 
Agradeço ainda a todos aqueles que, não contribuindo directamente para esta dissertação, prestaram uma 
ajuda muito valiosa no decorrer do trabalho laboratorial deste ano. Em particular agradeço à Doutora Paula 
Mota e ao Professor Doutor João Ramalho-Santos pela sua ajuda e cedência dos protocolos de histologia; à 
Doutora Paula Canas, à Doutora Paula Agostinho e ao Professor Doutor Rodrigo Cunha a sua preciosa ajuda e 
partilha de conhecimentos na técnica de imunohistoquimica, assim como no manuseamento do microscópio e 
pela disponibilidade que demonstraram. As técnicas acima mencionadas, apesar de não constarem desta 
Dissertação, foram uma importante parte do trabalho laboratorial desenvolvido ao longo deste ano. Agradeço 
também à Doutora Cláudia Pereira pela cedência dos anticorpos para a caspase-12 e citocromo c.  
 
Às minhas queridas amigas de curso e membros da “Equipa” deixo aqui o meu sincero obrigado por 
tudo o que partilhámos ao longo desta jornada. À Raquel e à Joana, que sempre ocuparão um lugar especial no 
meu coração, agradeço toda a amizade que partilhamos desde o primeiro dia, nos bons e maus momentos, tal 
como as imensas gargalhadas e momentos hilariantes que ficarão para sempre guardados na minha memória. À 
Tatiana e à Diana, as minhas principais companhias deste ano que passou, agradeço a amizade, os conselhos e a 
convivência que partilhámos, (quase) sempre com muito bom humor. À Inês Simões pela sua eterna paciência e 
bondade agradeço a sua valiosa amizade, boa disposição e todo o apoio e que sempre me prestou ao longo deste 
percurso. À Marina agradeço muito todo o incentivo, confiança e por tentar sempre tornar-me uma pessoa mais 
positiva e confiante, assim como as imensas gargalhadas e momentos de “parvoíce” e boa disposição. À Tânia, 
a nossa melhor fotógrafa, agradeço a sincera amizade, apoio e constante disponibilidade, à Inês Pita, Guida, e 
Mafalda resta-me agradecer o mais sinceramente possível a vossa amizade e companheirismo, e todos os bons e 
memoráveis momentos que partilhámos. As alturas de boa disposição e as longas conversas são coisas que 
nunca serão esquecidas. Agradeço também à Paula a amizade, e a preciosa ajuda e apoio que já me prestou, e 
também por ter sido uma grande companheira; aqui fica o meu sincero obrigado.  
À Mónica e à Cláudia, amigas da “terrinha”, agradeço a eterna amizade, ajuda e grande apoio ao longo 
de todo este percurso, foram as minhas mais fiéis amigas e companheiras, nos bons momentos recheados de 
bom humor e imensas gargalhadas, mas também nos momentos menos bons e mais dolorosos. Apesar de muitas 
vezes longe, sempre conseguiram estar perto, e aqui fica o meu enorme obrigado pela vossa paciência, valiosos 
conselhos e imperecível amizade. 
Aos restantes colegas de curso e amigos que a Vida entretanto afastou, a todos agradeço os momentos 
partilhados, porque todos em algum ponto do meu percurso contribuíram para o desfecho do mesmo e para a 
pessoa que hoje sou, e assim, aqui fica o meu obrigado.  
 
Por fim, aos meus pais, não tenho vocabulário suficiente para vos agradecer tudo o que me dão e fazem por 
mim, todo o apoio, ajuda, carinho, por estarem sempre lá, pela vossa dedicação, pelo incentivo que me dão, e 
pelos valores e educação que desde sempre me transmitiram. Sem vocês este objectivo não teria sido cumprido, 
e assim, aqui vos deixo o meu mais sincero obrigado. Quem eu hoje sou, a vocês o devo. 
 
O meu agradecimento ainda a todos aqueles que, de algum modo, contribuíram para a presente dissertação e 
que aqui não mencionei. 
 
 
 
 
i 
 
Index           
Resumo ………………………………………………………………………………………...... iii 
Abstract …………………………………………………………………………………………………………. vi 
Abbreviations …………………………………………...………………………………………………...…… viii 
CHAPTER 1 
INTRODUCTION AND AIMS ……………………………………………………………………………….. 1 
1. INTRODUCTION …………………………………………………………………………………...… 3 
1.1.  Molecular commonalities between T2D and AD ………………………………………………….. 3 
1.1.1. Dysfunctional mechanisms of cellular quality control in T2D and AD brains ……………… 4 
1.1.1.1.Autophagy ……………………………………………………………………………….. 5 
1.1.1.2. Main cell death mechanisms in T2D and AD brain: apoptosis and necrosis …………… 7 
a) Apoptosis ……………………………………………………………………………………. 7 
b) Necrosis ……………………………………………………………………………..……… 10 
1.1.2. Endogenous insulin/ insulin receptor signaling as the missing link between T2D and AD ...11 
1.1.2.1. The role of endogenous insulin in normal brain ………………………………………. 11 
1.1.2.2. Brain insulin/ IR dysfunction in T2D and AD ………………………………………… 11 
1.2.  Could anti-T2D therapies be also promising against AD? ……………………………………….. 12 
1.2.1. The main therapeutic goals in T2D management ………………………………………….. 12 
1.2.2. Exogenously-administered insulin as an anti-T2D and anti-AD therapy: the pros and cons..14 
1.2.3. Incretin-based anti-T2D drugs: GLP-1 receptor agonists and DPP-IV inhibitors …………. 15 
1.2.4. GLP-1 mimetics and GLP-1R agonists as potentially efficient drugs against 
neurodegeneration and AD ………………………………………………………………… 17 
1.2.4.1. GLP-1 mimetics: liraglutide …………………………………………………………... 17 
1.2.4.2. GLP-1R agonists: exendin-4, lixisenatide and albiglutide ……………………………. 18  
2. HYPOTHESIS AND AIMS ………………………………………………………………………….. 20 
CHAPTER 2  
2. MATERIALS AND METHODS …...………………………………………….……………21 
2.1.Materials …………………………………………………………………………………………… 23 
2.2. Animal characterization …………………………………………………………………………… 23 
2.3. Peripheral surgical implantation of Exe-4-containing micro osmotic pumps …………………….. 24 
2.4. Body weight ……………………………………………………………………………………….. 24 
2.5. Blood collection and plasma isolation …………………………………………………………….. 24 
2.6. Blood glucose levels ………………………………………………………………………………. 24 
2.7.GTT test ……………………………………………………………………………………………. 25 
2.8. HbA1c ………………………………………………………………………………………………. 25 
2.9. Plasma insulin levels and insulin resistance ……………………………………………………..... 25 
2.10. Blood cholesterol and triglyceride levels ………………………………………………………. 25 
ii 
 
2.11. Blood pressure …………………………………………………………………………………. 26 
2.12. Preparation of brain cortical membranes, cytosolic homogenates and isolated mitochondria ….26 
2.13. Protein quantification …………………………………………………………………………... 27 
2.14. Brain cortical GLP-1, insulin and glucose levels ………………………………………………. 28 
2.15. Western blotting analysis of brain cortical GLP-1R, Bcl2, Bax, cytochrome c, caspase 12  
cleavage, LC3II, P-mTOR, beclin-1, PI3K III, synaptophysin, PSD-95, RIP3 and 1 ……………... 29 
2.16. Co-immunoprecipitation of brain cortical IR and P-Tyr ………………………………………. 30 
2.17. Analysis of membrane lipids and DNA oxidation ……………………………………………... 30 
2.18. Colorimetric activation of caspases-like activities …………………………………………….. 31 
2.19. Data analysis and statistic ……………………………………………………………………… 32 
 
CHAPTER 3 
3. RESULTS ……………………………………………………………………………………...……… 33 
3.1. Animals’ peripheral characterization …………………………..…………………………..……… 35 
3.2. Chronic peripheral exendin-4 administration did not affect T2D GK rat brain weight …………… 39 
3.3. Effect of chronic peripheral treatment with exendin-4 on GK rat brain cortical GLP-1 levels and 
GLP-1R protein expression ………………………………………………………………………… 39 
3.4. The role of chronic subcutaneous exendin-4 treatment on GK rat brain cortical insulin levels and IR 
protein expression ………………………………………………………………………………….. 40 
3.5. Effect of chronic subcutaneous exendin-4 administration on GK rat brain cortical glucose levels...41 
3.6. The role of chronic subcutaneous exendin-4 treatment on oxidative stress markers in GK rat brain 
cortex ……………………………………………………………………………………………….. 42 
3.7. Effect of chronic peripheral administration of exendin-4 on autophagic mechanism in GK rat brain 
cortex ……………………………………………………………………………………………….. 42 
3.8. Effect of peripheral exposure to exendin-4 on apoptotic cell death in GK rat brain cortex………...44 
3.9. The role of peripheral administration of exendin-4 on necrotic cell death in GK rat brain cortex…48 
3.10. Effect of peripheral administration of exendin-4 on synaptic function in GK rat brain cortex….48 
 
CHAPTER 4  
DISCUSSION …………………..……………………………………………………………………………... 51 
 
CHAPTER 5 
CONCLUSION ……………………………………………………………………………………………….. 57 
 
CHAPTER 6  
BIBLIOGRAPHY ……………………………………………………………………………………….……. 61 
 
 
iii 
 
Resumo 
 A Diabetes tipo 2 e a doença de Alzheimer são, nos dias de hoje, dois graves problemas de saúde 
pública. A diabetes tipo 2 afecta milhões de pessoas em todo o mundo e os seus números continuam a aumentar. 
Esta epidemia tem grandes repercussões no quotidiano dos pacientes, maioritariamente devido às suas 
complicações crónicas que podem afectar não apenas vários órgãos periféricos, mas também o cérebro, 
constituindo inclusivamente um factor de risco para o desenvolvimento da doença de Alzheimer. Esta é a forma 
de demência mais comum, na qual a resistência à insulina (uma das características da diabetes tipo 2) tem sido 
amplamente descrita, pelo que tem sido colocada a hipótese de que a doença de Alzheimer e a Diabetes tipo 2 
serão mais do que meras patologias não interrelacionadas. De facto, um número crescente de evidências 
científicas sugere a existência de inúmeros elos moleculares de ligação entre as duas patologias (ex.: 
dismetabolismo da glucose, insulina e disfunção mitocondrial, stresse oxidativo), que poderão culminar em 
morte celular e consequente disfunção cerebral. Assim, a doença de Alzheimer tem sido cada vez mais referida 
como uma “diabetes tipo 3” ou uma “diabetes tipo 2 específica do cérebro”. Nesta perspectiva, tem sido 
recentemente sugerido que fármacos eficientes contra a diabetes tipo 2 poderão também constituir uma 
estratégia terapêutica contra a demência (particularmente contra a doença de Alzheimer). Um dos fármacos 
anti-diabéticos potencialmente promissores é a exendina-4, pertencente à classe das incretinas/agonistas dos 
receptores do GLP-1 (correspondente a glucagon-like peptide-1) e já utilizado clinicamente no tratamento da 
diabetes tipo 2. Além do seu efeito insulinotrópico a nível periférico, por se tratar de um fármaco sintético do 
tipo das incretinas, a exendina-4 possui a capacidade de induzir o chamado “efeito incretina” (promove a 
secreção de insulina dependente de glucose), sendo resistente à degradação por parte da enzima dipeptidil 
peptidase-IV e diminuíndo o risco de hipoglicemia frequentemente associado aos fármacos anti-diabéticos 
“tradicionais”. Adicionalmente, tem sido descrito que a exendina-4 reduz a ingestão de alimentos e, desta 
forma, poderá constituir uma terapia anoréctica eficaz. Mais relevante para este estudo parece ser o número 
crescente de evidências de que a exendina-4 poderá desempenhar também um papel neuroprotector, estando 
inclusivamente a decorrer vários ensaios clínicos neste sentido. Contudo, os mecanismos moleculares precisos 
subjacentes à neuroprotecção pela exendina-4 contra a disfunção cognitiva associada a diabetes tipo 2 e doença 
de Alzheimer continuam por esclarecer. 
 Desta forma, no presente estudo colocámos a hipótese de que a exendina-4 melhora as alterações 
periféricas associadas à diabetes tipo 2, bem como dos mecanismos intracelulares de controlo de qualidade no 
cérebro, neurodegeneração e morte celular, melhorando assim a função sináptica e, em última análise, a função 
cognitiva em condições de diabetes tipo 2. Assim, tivemos como objectivo principal analisar o potencial efeito 
neuroprotector da administração contínua, crónica e periférica com exendina-4, utilizando para este efeito o 
cérebro de ratos meia-idade, diabéticos tipo 2. Mais especificamente, avaliámos o papel da administração 
crónica periférica de exendina-4 em ratos diabéticos tipo 2, ao nível dos seguintes parâmetros periféricos: 1) 
características patológicas (níveis sanguíneos de glucose, taxa de remoção de glucose do sangue, níveis de 
insulina e hemoglobina glicosilada no plasma e resistência à insulina); 2) outros factores de risco associados à 
diabetes tipo 2 (como o peso corporal, hipercolesterolémia e elevada pressão sanguínea), assim como em 
amostras de córtex cerebral: 3) marcadores de stresse oxidativo, 4) (dis)função sináptica, 5) mecanismos de 
controlo de qualidade celular (autofagia) e 6) neurodegeneração e morte celular necrótica e apoptótica 
(dependente e independente de caspases).  
 No presente estudo foram utilizados homogeneizados de córtex cerebral de ratos não-diabéticos Wistar e 
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diabéticos tipo 2 não-obesos Goto-Kakizaki, ambas as estirpes correspondiam a ratos de 8 meses, submetidos 
continuamente (ou não) à administração periférica de exendina-4 (5 g/kg/dia, velocidade de infusão de 2.5 
l/h), durante 28 dias, mediante implantação subcutânea de bombas micro-osmóticas Alzet. Os animais foram 
monitorizados antes e periodicamente durante o tratamento, no sentido de avaliar o seu bem-estar dos animais e 
o sucesso do tratamento. No final deste, os ratos foram eutanasiados e os parâmetros sanguíneos relacionados 
com a diabetes tipo 2 e os seus factores de risco mais comuns foram determinados. Adicionalmente, foram 
preparados homogeneizados citosólicos corticais e respectivas fracções mitocondriais isoladas, de  modo a 
serem utilizados na quantificação dos níveis de GLP-1, insulina e glucose, bem como nos níveis de expressão 
proteica do receptor do GLP-1 e na activação do receptor de insulina, mediante aplicação das técnicas de 
ELISA, “western blotting” ou co-imunoprecipitação. Seguidamente, procedeu-se à determinação, por 
colorimetria, ELISA ou “immunoblotting”, de vários marcadores de oxidação de lípidos e ADN, autofágicos, de 
apoptose dependente e independente de caspases e de necrose. Finalmente, o papel de exendina-4 na função 
sináptica do córtex de cérebros de ratos diabéticos tipo 2 foi também avaliado por “western blotting”. 
 No presente estudo, observámos que a administração contínua periférica de exendina-4 pareceu 
suplantar as características patológicas periféricas associadas à diabetes tipo 2 (hiperglicemia, menor taxa de 
remoção de glucose do sangue, níveis elevados de hemoglobina glicosilada e resistência à insulina). Além disso, 
a exendina-4 recuperou os níveis de GLP-1 no córtex cerebral de ratos GK e, apesar de não ter mostrado efeitos 
significativos na expressão proteica do receptor do GLP-1, não descartamos a hipótese de que o fármaco 
melhore a actividade deste receptor no cérebro. Todavia, a clarificação deste assunto requer estudos adicionais. 
Surpreendentemente, a exendina-4 não afectou os níveis corticais de insulina nem a activação do seu receptor, 
sugerindo que este poderia não estar directamente envolvido nos efeitos subsequentes da exendina-4 no cérebro 
de ratos GK. Tais efeitos incluíram o restabelecimento dos níveis de glucose no cérebro e uma tendência para a 
exendina-4 proteger contra a oxidação lipídica e do ADN. Notavelmente, os nossos resultados também 
apontaram para uma activação tendencialmente maior do processo autofágico no córtex cerebral dos ratos GK 
tratados com exendina-4, provavelmente constituindo uma estratégia protectora contra a morte celular mediada 
pela caspase-3 associada à diabetes tipo 2 nos ratos GK tratados com solução placebo. De acordo com esta 
sugestão, a exendina-4 pareceu inibir a apoptose induzida pela caspase 3 no córtex cerebral dos ratos GK 
diabéticos tipo 2, provavelmente devido à (pelo menos parcialmente) sua tendência para reter a proteína anti-
apoptótica Bcl2 e a pro-apoptótico citocromo c na mitocôndria, enquanto a Bax (outra proteína pro-apoptótica) 
permaneceu no citosol, originando posteriormente uma ligeira melhoria na função cortical dos ratos diabéticos 
tipo 2 expostos a exendina-4. 
 Em suma, os nossos resultados sugerem que, através de uma melhoria das características patológicas 
periféricas da diabetes tipo 2, a terapia crónica com exendina-4 por via subcutânea poderá ter um impacto 
benéfico no córtex cerebral de ratos machos, não obesos e diabéticos tipo 2 de meia-idade, através do 
restabelecimento dos níveis de GLP-1 e protegendo contra eventuais danos associados a hiperglicemia local e 
stresse oxidativo. Essa protecção pela exendina-4 provavelmente envolverá uma estimulação “fisiológica” dos 
mecanismos de autofagia, com o consequente impedimento da morte celular apoptótica e da disfunção 
sináptica. Nesta perspectiva, a administração crónica periférica de exendina-4 poderá constituir uma abordagem 
terapêutica promissora contra as complicações a longo-termo da diabetes tipo 2, nomeadamente as que afectam 
directamente o cérebro. 
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Abstract  
Type 2 diabetes (T2D) and Alzheimer disease (AD) are two major health care issues nowadays. T2D 
affects millions of people worldwide, whose number continues to increase. This epidemic has major 
repercussions in the patients’ daily life, mainly due to its chronic complications that can affect not only several 
peripheral organs, but also the brain, and constitutes a risk factor for development of AD. AD is the most 
common form of dementia, in which insulin resistance (one of main hallmarks of T2D) has been widely 
described, thus rendering both AD and T2D more than mere unrelated pathologies. Indeed, increasing evidences 
suggest that T2D and AD share several common molecular links (e.g. glucose dysmetabolism, insulin and 
mitochondrial dysfunction, oxidative stress) that culminate in brain dysfunction and cell death. As such, AD has 
been increasingly referred to as “type 3 diabetes” or a “brain-specific T2D”. In line with this, it has been 
recently hypothesized that efficient drugs against T2D could be also a beneficial therapeutic strategy against 
dementia (particularly AD). And one of such potentially promising anti-T2D drugs is exendin-4 (Ex-4), a 
already clinically used compound from the incretin/glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) 
agonists class of anti-T2D drugs. Besides its peripheral insulinotropic effect, as a synthetic incretin-like 
compound, Ex-4 is known to have an incretin effect (promoting a glucose-dependent insulin secretion), being 
resistant to dipeptidylpeptidase-IV (DPP-IV) degradation and lowering the risk of hypoglycemia, often 
associated to the “traditional” anti-T2D therapies. Importantly, Ex-4 has been also described as a potential food 
intake reducer, an anorectic drug and, most importantly herein, a highly promising neuroprotective agent, with 
clinical trials already ongoing in this line. However, the knowledge on the precise molecular mechanisms 
underlying such neuroprotection against chronic T2D-associated cognititve dysfunction and AD remain unclear. 
Under this perspective, we hypothesized that Ex-4 restores the T2D-associated alterations in intracellular 
quality control mechanisms, neurodegeneration and death, thereby improving synaptic function and, ultimately, 
cognitive function. Therefore, our main goal was to study the potential neuroprotective effect of chronic, 
continuous peripheral Ex-4 treatment in middle-aged T2D rat brain. More specifically, we evaluated the role of 
chronic peripheral Ex-4 administration in T2D: 1) pathological features (blood glucose levels, rate of glucose 
clearance from blood, plasma insulin and glycosylated hemoglobin A1C (HbA1C) levels and insulin resistance); 
2) other T2D-associated risk factors (as body weight, hypercholesterolemia, hypertriglyceridemia and high 
blood pressure), as well as in 3) rat brain cortical markers of oxidative stress, 4) synaptic (dys)function, 5) 
cellular quality control (autophagic) mechanisms and 6) neurodegeneration, caspase-dependent and –
independent apoptotic and necrotic cellular death.  
Herewith, we used middle-aged (8 month old) non-diabetic male Wistar and non-obese, T2D Goto-
Kakizaki (GK) rat brain cortical homogenates, either submitted or not to the continuous peripheral delivery of 
Ex-4 (5 g/kg/day, at an infusion rate of 2.5 l/h), for 28 days, upon subcutaneous implantation of micro-
osmotic Alzet pumps. Animals were monitored before and periodically during treatment to determine animals’ 
welfare and treatment’s success. At the end of treatment, rats were euthanized and peripheral blood parameters 
related with T2D and its commonly associated risk factors were determined. Additionally, brain cortical 
cytosolic homogenates and isolated mitochondrial fractions were obtained to be used in the quantification of 
GLP-1, insulin and glucose levels, GLP-1R protein expression levels and insulin receptor (IR) activation, by 
ELISA, western blotting or co-immunoprecipitation. This was followed by the colorimetric, ELISA or 
immunoblotting determination of several lipid and DNA oxidation, autophagic and caspase-dependent and –
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independent apoptosis markers, as well as of necrotic markers. Finally, the role of Ex-4 on T2D-related brain 
cortical synaptic function was also evaluated by western blotting. 
We observed that the continuous peripheral administration of Ex-4 was able to overcome the peripheral 
T2D pathological hallmarks (hyperglycemia, rate of glucose clearance from blood, HbA1C levels and insulin 
resistance). Moreover, Ex-4 restored brain cortical GLP-1 levels in GK rats and, despite no significant effects 
on GLP-1R protein expression, it is possible that the drug may improve its activity in brain. However, this 
deserves further analysis. Surprisingly, Ex-4 did not interfere with brain cortical insulin levels or its receptor 
activation, suggesting that these may not be directly involved in the subsequent effects of Ex-4 in GK rat brain. 
Such effects include a restoration of brain glucose levels and a tendency for Ex-4 to protect against lipid and 
DNA oxidation. Notably, our results also pointed towards a tendentially higher activation of the autophagic 
process in brain cortices from the Ex-4-treated GK rats, probably as a protective strategy against the 
subsequently reported T2D-related caspase-3-mediated death in placebo-treated GK rats. Indeed, Ex-4 appeared 
to inhibit the caspase-3-induced apoptosis in T2D GK rat brain cortices, probably due (at least partially) to its 
tendency to retain the anti-apoptotic Bcl2 and the proapoptotic cytochrome c within mitochondria, whereas the 
proapoptotic Bax remained in the cytosol, ultimately leading to a slightly improved brain cortical function in 
Ex-4-exposed T2D rats. 
Altogether, our results suggest that by ameliorating the peripheral T2D pathological hallmarks, chronic 
continuous subcutaneous Ex-4 has a beneficial impact in middle-aged non-obese T2D male rat brain cortex, 
restoring GLP-1 levels and protecting against local hyperglycemia- and oxidative stress-mediated injury, 
probably via the stimulation of a physiological-like autophagy and the subsequent hampering of apoptotic death 
and synaptic dysfunction. In sum, chronic peripheral Ex-4 administration may constitute a potential therapeutic 
approach against long-term complications of T2D per se affecting the brain.  
 
Keywords: Type 2 diabetes, Alzheimer disease, anti-T2D drugs, incretin, GLP-1, exendin-4   
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1. INTRODUCTION 
Given its ever increasing number of patients worldwide, diabetes Mellitus (DM) is nowadays a growing 
health care issue and a modern epidemic, with recent estimates pointing to an increase from 285 million to 439 
million diabetics between 2010 and 2030 
1
. There are several types of diabetes, but the two major forms are 
type 1 (T1D) and type 2 diabetes (T2D), with the later accounting for more than 90% of all cases and, thus, 
unquestionably constituting a major public health concern 
1,2
.  
One of the major pathological hallmarks of T2D is hyperglycemia that may arise from insulin resistance. 
This in turn may progress towards pancreatic β-cell failure and a generalized loss of insulin sensitivity in the 
later phases of the disease. Physiologically, β-cells can compensate for the loss of insulin sensitivity by other 
cells in the body 
3
. However, and despite initially not depending on exogenous insulin administration, T2D 
patients may at some point need this hormone to control blood glucose levels, particularly when diet alone or 
treatment with oral hypoglycemic agents become inefficient 
4
.  
Although traditionally T2D was more common  in people aged above 30 years, currently its incidence is 
also increasing among younger people 
5
, probably as a result of other risk factors (besides aging) associated 
with modern lifestyle, namely high blood pressure, sedentarism and metabolic syndrome 
6
. Interestingly, 
metabolic syndrome constitutes a group of disorders (e.g. dyslipidemia and obesity) also highly related with 
cardiovascular disease 
1,7,8
. Besides all this, T2D also poses a huge socio-economic burden due to its commonly 
associated long-term complications that may lead, e.g., to brain structural and functional alterations 
9
. Notably, 
amongst such long-term deleterious influence of T2D in brain, it is included its wide implication as a risk factor 
for dementia (both vascular dementia and Alzheimer disease (AD)) 
10
, with aging constituting also a well-
known common risk factor to both T2D and AD 
11
. And, surprisingly, in the Mayo Clinic Alzheimer Disease 
Patient Registry, Janson et al. (2004) reported that both T2D and impaired fasting glucose were more prevalent 
in AD than in non-AD individuals, with 81% of AD patients exhibiting either T2D or impaired fasting glucose 
12
.  
 Several mechanisms have been hypothesized on the increased neurodegeneration and impaired cognition 
in T2D. For instance, it has been increasingly suggested a pivotal role for insulin resistance (and/or impaired 
insulin signaling), particularly upon aging 
13,14
. And in line with this, AD has been increasingly recognized as a 
neuroendocrine-like disorder, a so-called “type 3 diabetes” 15,16 or a “brain-specific T2D” 17. Given the close 
relation between both disorders, it has been also increasingly accepted that an accurate and early diagnosis of 
T2D, a provision of durable glycemic control and, at least in the initial phases of the disease, a convenient 
prevention of chronic complications (e.g. by the adoption of an healthy lifestyle, body weight control or 
moderate physical exercise) may be crucial to successfully fight against these epidemics. However, as disease 
progresses, some pharmacological approach (including combined therapy) may be required to successfully deal 
with T2D and its complications In this regard, the development of more efficient preventive anti-T2D therapies 
(and with less secondary effects) that also minimize any further damage to the already injured organs is of a 
crucial relevance to further avoid the development of long-term T2D complications, including AD.  
 
1.1. Molecular commonalities between T2D and AD 
 
Besides impaired insulin signaling, other abnormal biochemical mechanisms common to both T2D and 
AD include glucose dysmetabolism, mitochondrial dysfunction, increased oxidative stress or deposition of 
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amyloidogenic proteins, which, if not efficiently dealt by the cells, may ultimately lead to neurodegeneration 
and death 
2
.  
Physiologically, neurons are unable to store and synthesize glucose (their main metabolite) and, thus, it 
has to be transported from the periphery, cross the blood-brain barrier (BBB) and target the brain. This occurs 
mostly via the glucose transporters (GLUTs) isoforms GLUT-1, GLUT-3 and GLUT-4 (the most abundant 
isoforms) 
18
. However, under chronic glucose dysmetabolism (as in T2D) several brain damaging effects may 
occur, including the formation and accumulation of highly deleterious advanced glycation endproducts (AGEs) 
19
. These AGEs arise after a sequence of events that start by the reaction between reducing sugars (e.g. glucose 
and fructose) and amino groups from proteins, yielding the end products of the Maillard reaction, which then 
become auto-oxidized and form cross-linked complexes and unstable compounds 
16
. Although massive AGEs 
formation has been widely described in diabetic patients, they have been also detected in retinal vessels, 
peripheral nerves, kidneys, and central nervous system (CNS) of aged patients 
20
. Importantly herein, the extent 
of AGEs-induced glycation of amyloid-β peptide (Aβ) being correlated with its aggregation into senile plaques, 
as well as with abnormally increased tau protein phosphorylation and consequently with neurofibrillary tangles 
(NFTs) formation 
2
 - the two main neuropathological hallmarks of AD 
16
. Besides this, AGEs reaction with free 
radicals is also known to exacerbate oxidative damage and, ultimately, cellular damage 
11
. In this regard, as 
T2D also accelerates the production of such deleterious molecules, it is not surprising that AGEs production 
(and eventually the vicious cycle of oxidative stress) may constitute an additional potential pivotal link between 
T2D and increased risk of AD.  
Besides AGEs, another common mechanism to both pathologies is mitochondrial dysfunction 
7
. 
Although mitochondria are primarily responsible for several crucial cellular processes and the main 
coordinators of energy metabolism (they generate over 90% of cellular adenosine trisphosphate (ATP) 
2
, they 
are also one of the major sources and targets of reactive oxygen species (ROS), which in turn are known to play 
a pivotal role in the pathogenesis of both AD and diabetes
21. Thus, given mitochondria’s high susceptibility to 
oxidative stress-mediated injury and the neurons’ extreme sensitivity to alterations in their mitochondrial pool, 
it is plausible their dysfunction might be correlated with AD and diabetes. In this regard, our group has recently 
demonstrated that respiratory chain and phosphorylation systems were similarly impaired in brain mitochondria 
from both the 3xTgAD and chronically sucrose-treated mice (models for AD and T2D, respectively) 
22
. This, 
together with an increased oxidative dysfunction could underlie their similar behavioral and cognitive 
abnormalities, including increased fear and anxiety and impaired learning and memory. Besides this, an 
increased brain cortical and hippocampal Aβ accumulation was reported in sucrose-treated mice, thereby point 
towards the development of AD features in T2D as a consequent of a metabolic dysfunction 
22,23
. Importantly, 
these results were in line with previous reports on T2D patients predisposition for cognitive decline and 
eventually AD 
24
, as well as with other very recent studies in our group reporting an association between central 
insulin resistance and brain cortical and hippocampal profound mitochondrial abnormalities, and increased Aβ 
accumulation, tau protein hyperphosphorylation, neurodegeneration and death 
25
. 
 
1.1.1. Dysfunctional mechanisms of cellular quality control in T2D and AD brains 
 
Under physiological conditions, neuronal cells’ homeostasis is maintained, e.g., by protein quality-
control mechanisms. Thus, in the presence of misfolded proteins, the intracellular activation of the ubiquitin-
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proteosome system and/or autophagy-lysosome pathway determines the degradation or recycling of such 
abnormal proteins, avoiding their maintenance in the cell 
26,27
. However, once these systems become 
dysfunctional, the accumulation and aggregation of altered proteins occur, ultimately leading to the cellular 
toxicity and neurodegeneration typical from, e.g., AD and other neurodegenerative pathologies 
28
. 
 
1.1.1.1 Autophagy 
Autophagy is an evolutionarily conserved catabolic process that targets cellular organelles and other 
cytoplasmic constituents (as aged, dysfunctional proteins) for lysosomal recycling or degradation 
29
. Several 
stimuli can induce autophagy, including starvation, hypoxia and chemical toxins (the most well known is 
rapamycin)
30
 and its activation has been implicated in numerous distinct cellular processes (e.g. cell survival, 
cell death and pathogen clearance) 
31
. Pathologically, strong genetic and animal data support a direct association 
between dysfunctional autophagy and cancer, neurodegenerative diseases and chronic inflammation 
32–34
.  
One of the most widely used and arguably the most physiologically relevant stimulus for autophagy has 
been nutrient starvation 
35
, whose cellular detection and subsequent autophagic regulation involve nutrient-
sensitive kinases, such as mammalian target of rapamycin complex 1 (mTORC1) and AMP-activated protein 
kinase (AMPK) 
36
. AMPK is a serine/threonine kinase activated by metabolic stress or ATP consumption, 
leading to the activation of a wide variety of catabolic processes (as glucose uptake and metabolism), whilst 
several anabolic pathways (e.g. lipid, protein, and carbohydrate biosynthesis) are simultaneously inhibited 
37
. 
On the other hand, target of rapamycin (TOR) is another highly evolutionarily conserved serine/threonine 
protein kinase that occurs from yeast to mammals (the mammalian target of rapamycin (mTOR)) 
38
. Initially, 
TOR protein was merely identified as a target of rapamycin, but then it was also shown to regulate rapamycin-
induced autophagy in yeast, even under nutrient-rich conditions 
39
. Interaction between TOR proteins and their 
binding partners leads to the formation of at least two functionally distinct complexes in yeast: the so-called 
TOR complex 1 (TORC1) and TORC2, with rapamycin binding exclusively to TORC1 whereas mTORC2 is 
unaffected by rapamycin treatment 
40
. Importantly, mTORC1 activity depends on several positive signals (such 
as high energy levels, normoxia, amino acids, or growth factors) to culminate in autophagic inhibition, whereas 
AMPK activation occurs under energy-low conditions and has been associated with autophagy induction 
41
.  
Three types of autophagy have been identified to date: macroautophagy, microautophagy and 
chaperone-mediated autophagy (Fig. 1.1). In literature, the term “autophagy” usually corresponds to 
macroautophagy, which is characterized by the formation of double membrane vesicles – the autophagosomes 
35
. Macroautophagy was first genetically characterized in yeast, yielding to the identification of a family of 
autophagy-related genes (ATG) that function as its direct executioners 
42
. More specifically, the yeast ATG8 
and its mammalian homologue microtubule-associated protein light-chain 3 (LC3) are key autophagic-related 
proteins, which are recruited to the autophagosomal double-membranes 
43
, thereby monitoring the mammalian 
autophagosomal formation for subsequent sequestration of material to be delivered to lysosomes 
29
. Besides 
LC3, beclin-1 is another pivotal protein on the autophagic process, being a mammalian orthologue of yeast 
Atg6 highly involved in the vesicle formation during autophagy 
44
 and actively cooperating with the 
phosphoinositide 3-kinase (PI3K) pathway to enhance the formation of the autophagic vacuoles 
29
. Hence, 
beclin-1 has been also commonly used to monitor autophagic activity.  
In microautophagy, lysossomes engulf small cytosolic components through invagination of the 
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lysossomal membrane directly into its lumen 
45
. This dynamic reportedly resembles the formation of 
multivesicular bodies (MVBs) in the late endosome 
46
. On the other hand, during chaperone-mediated 
autophagy, a selective lysosomal pathway for the degradation of cytosolic proteins, these are directly 
translocated into lysossomes by means of lysosomal associated membrane protein-2A (LAMP-2A) 
47
. This 
process is a secondary response to starvation in mammals and does not involve any membrane reorganization 
48
.  
Studies from our group on the relation between brain mitochondrial dysfunction upon DM and/or AD 
and autophagy provided evidence that, upon insulin signaling-mediated activation of autophagy, the subsequent 
degradation of aged and dysfunctional proteins was accompanied by an increase in the aminoacid pool, which 
could provide the energy necessary for the synthesis of new proteins 
49,50
. This hypothesis was further supported 
by a recent study involving streptozotocin (STZ)–induced T1D rats treated with insulin 51. In insulin-treated 
T1D rats, lower LC3-II levels compared to non-treated diabetic animals were accompanied by a decrease in tau 
protein phosphorylation at the serine 396 residue 
51
, suggesting that a decrease in autophagy activation in the 
insulin-treated animals could be related with a stimulation of calpain-mediated tau degradation and, ultimately, 
with a decrement in tau protein phosphorylation 
52
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Different types of autophagy. In macroautophagy, a portion of cytoplasm (including organelles) is enclosed 
by an isolation membrane (the phagophore) to form an autophagosome, whose outer membrane then fuses with the 
lysosome and allows for degradation of its content in the resulting autolysosome. In microautophagy, small pieces of the 
cytoplasm are directly engulfed by inward invagination of the lysosomal or late endosomal membrane for subsequent 
degradation. Chaperone-mediated autophagy involves the recognition of substrate proteins and co-chaperones. Then, they 
bind with lysosomal LAMP-2A, being translocated into the lysosomal lumen. Regardless the type of autophagy activated, 
the resulting degradation products can be used for, e.g., new protein synthesis, energy production or gluconeogenesis. 
[Adapted from Mizushima and Komatsu, 2011]. 
 
Despite the extensive literature, the precise role of autophagy in AD is still not fully understood. In vitro 
studies reported that under nutrient deprivation, treatment with Aβ25-35 and Aβ1-42 induced autophagy in a SH-
SY5Y cell line overexpressing EGFP-LC3 
53
. Moreover, Hung et al. (2009) demonstrated that using the ATG7 
siRNA to inhibit the formation of autophagosomes early in the process significantly enhanced Aβ-induced 
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neurotoxicity 
53
. Additionally, neuronal exposure to Aβ promoted autophagosomal formation and protected 
against the development of apoptotic characteristics, whereas the inhibition of autophagy exacerbated neuronal 
apoptosis 
54
. Furthermore, lysosomal autophagy has been also reported to play a role in the clearance of tau 
protein (which when dysfunctional, results in the formation of tau oligomers) 
55
. Overall, these observations led 
to the hypothesis that autophagy could have a neuroprotective role against Aβ-induced neurotoxicity 50. 
Nevertheless, others reported that autophagy could contribute to the degeneration of dystrophic neurites. In line 
with this, Yu et al. (2004, 2005) 
30,56
 showed that autophagic vesicles contain amyloid precursor protein (APP) 
and a high content of β-secretase (BACE), necessary to generate Aβ. This was supported by the detection of 
both Aβ1-40 and Aβ1-42 in purified autophagic vesicles from transgenic mice overexpressing APP 
30,56
. 
Accordingly, it was demonstrated that the AD-induced impairment in the maturation of autophagosomes and in 
their retrograde transport towards the neuronal soma leads to a large accumulation of autophagic vesicles along 
dystrophic and degenerating neurites, which could contribute to the local accumulation of Aβ within plaques 57. 
Moreover, the functional disruption in the endocytic pathway, together with an overexpression of lysosomal 
system components in AD may exacerbate Aβ overproduction and consequent neuronal death 58. Importantly 
herein, it was recently found that the brains of patients with advanced AD had a reduced expression of beclin-1, 
which was consistent with reports on the decreased neuronal autophagy in a transgenic mouse model of AD 
with deletion of beclin-1, as well as with an increased accumulation and deposition of intraneuronal Aβ 59. 
Consistently, upon mTOR inhibition with rapamycin and the subsequent signaling restoration, cognitive deficits 
were rescued and Aβ and tau levels improved, probably due to increased activation of autophagy 49. 
From the above, most evidences appear to support a neuroprotective role for autophagy in the early 
stages of AD pathology, whilst as disease progresses autophagy will probably potentiate neuronal degeneration 
and death. 
 
1.1.1.2. Main cell death mechanisms in T2D and AD brain: apoptosis and necrosis 
a) Apoptosis  
Under physiological conditions, apoptosis is a crucial biological process throughout the organism, but 
most particularly in the nervous system, whereby it regulates the development and tissue homeostasis. 
However, apoptosis deregulation may lead to several pathological alterations, including developmental defects, 
autoimmune diseases or cancer 
60
. During brain development, cell death is essential for the regulation of 
neuronal cell number and to protect against the propagation of damaged cells, whereas its deregulation in the 
adult nervous system has been implicated in neurodegeneration and neurodegenerative disorders 
61
. 
Morphologically, apoptosis is characterized by cell membrane blebbing, cell shrinkage and chromatin 
condensation, followed by DNA fragmentation, engulfment by macrophages or other neighboring cells (to 
avoid an inflammatory response in surrounding tissues) 
62
. Additionally, apoptosis may be accompanied by 
phosphatidylserine exposure on the outer leaflet of the plasma membrane, as well as by changes in 
mitochondrial membrane permeability, with the subsequent release of mitochondrial proteins (e.g. cytochrome 
c) from the intermembrane space 
63
. 
There are two main apoptotic pathways: the extrinsic (or death receptor pathway) and the intrinsic 
pathways (also known as the mitochondrial pathway) 
64
: 
- The extrinsic pathway - can be initiated by numerous external stimuli, including binding of death-inducing 
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ligands to cell surface receptors 
65
. This cascade usually involves cell surface death receptors (namely Fas, 
tumor necrosis factor (TNF) receptor (TNFR), or TRAIL receptors) that oligomerize upon death ligand 
stimulation, thereby recruiting the adaptor protein Fas-associated death domain (FADD) and caspase-8 to form 
a death-inducing signaling complex (DISC). Autoactivation of caspase-8 at the DISC then activates downstream 
effector caspases (including caspases-3, -6 and -7) to further continue the cell death program 
66
. 
- The intrinsic pathway – can be initiated by intrinsic signals (such as irradiation- or chemically-induced DNA 
damage, growth factor deprivation or oxidative stress) that ultimately may involve mitochondria, with the 
release of mitochondrial cytochrome c into the cytoplasm and the subsequent induction of a caspase cascade. 
More specifically, once in the cytosol cytochrome c binds to the apoptosis protease-activating factor 1 (Apaf-1) 
and procaspase-9, generating an intracellular DISC-like complex known as “apoptosome”, where caspase-9 is 
activated and subsequently processes caspase-3 
67
.  
Importantly, we must bear in mind that both extrinsic/death receptor and intrinsic/mitochondrial 
apoptotic pathways may ultimately converge on caspase-3 to drive the terminal events of programmed cell 
death 
60
.  
Regarding caspases, these apoptotic executioners are cysteine proteases that use the sulfur atom in 
cysteine to cleave polypeptide chains. These enzymes search for a specific sequence in their target proteins, 
cleaving their substrates typically on the carboxyl side of aspartate amino acids (thus the name “caspase”: “c” 
for cysteine protease and “asp” for the strong aspartate preference) 68,69. According to the specific substrates 
cleaved by each caspase during apoptosis progression, typical biochemical and morphological changes arise, 
thus rendering the detection of activated caspases a noteworthy marker of this type of cell death 
70
. 
Traditionally, initiator caspases were considered to be autoproteolytically activated when closely to each other – 
this was called the induced proximity model 
66
. Later on, this model was refined to the proximity induced 
dimerization model, according to which the apoptosome promotes caspase-9 homodimerization due to its 
increased local concentration 
71
. Likewise, DISC induces dimerization and consequent auto-activation of 
caspase-8 
72
. Accordingly, activated  initiator caspases will normally cleave and activate effector procaspases, 
which then cleave several downstream death substrates to induce cell death 
73
. Accordingly, several lines of 
evidence suggest that the three downstream effector caspases (caspases-3, -6 and -7) are usually more abundant 
and active than the upstream “initiator” caspases-8 or -9 74. Nevertheless, genetic evidence has shown that loss 
of caspase-3 may also result in gross brain malformations and premature death 
75
, with caspase-3 knockout mice 
also displaying a defective response to both intrinsic and extrinsic apoptotic pathways stimuli 
76
. Thus, caspase-
3 has been recognized as the crucial executioner caspase 
60
. 
From the above, we can infer that mitochondria is a central regulator of the intrinsic apoptotic pathway, 
with mitochondrial outer membrane permeabilization (MOMP) playing a crucial role herein 
77
. Importantly, 
MOMP mediation and control is known to involve the Bcl-2 family members, which in turn are also key 
regulators of apoptosis 
78
. Bcl-2 family of proteins involves both pro- and antiapoptotic proteins that share 
sequence homology in Bcl-2 homology (BH) domains 
79
. Regarding the antiapoptotic group of proteins (as Bcl-
2 and Bcl-xL), their homology occurs in four BH domains (BH1 to 4), whereas the proapoptotic ones can in 
turn be subdivided into the “multidomain” and the “BH3-only” subfamilies 80. The multidomain proapoptotic 
subclass includes Bax and Bak, that display homology in BH domains 1-3, while the BH3-only proteins (e.g. 
Bid and Bim) although structurally similar to multidomain family members, their sequence similarity is limited 
to the BH3 domain 
80
.  
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Under physiological conditions, Bax proteins reside in the cytosol and do not dimerize with each other 
or with other Bcl-2 family members. However, upon the induction of apoptosis, Bax proteins acquire an active 
conformation and translocate into mitochondrial and endoplasmic reticulum (ER) membranes, thereby forming 
homo-oligomers or heterodimerizing with other Bcl-2 family members, resulting, e.g., in Bax/Bcl-2 
heterodimers 81.  
In 1999, Russel et al. observed that hyperglycemia, a hallmark of T2D, induced neurite degeneration and 
several apoptotic features (including activation of caspase-3) in rat dorsal root ganglion neurons 
82
. These 
results were correlated with the observation, in an in vivo hyperglycemic model, of nuclear and cytoplasmatic 
apoptotic changes on top of disruption of mitochondria functionality in dorsal root ganglion neurons and 
Schwann cells 
82
. 
As previously referred, AD is the best known form of dementia, characterized by an impaired cognition 
that has been strongly correlated with synaptic degeneration and neuronal death in the hippocampus, amygdala 
and associated regions of the cerebral cortex, probably as the result of Aβ peptide-enriched amyloid plaque 
formation 
83
. But the most striking herein was that, besides these classic Aβ deposits, neurons from AD patients 
also displayed an increased caspase activity, damaged DNA and alterations in the expression of Bcl-2 family 
members 
84
, pointing towards an apoptotic-mediated neuronal death. These observations were further supported 
by the induction of apoptosis upon exposure of cultured neurons to Aβ, in a process involving increased 
oxidative stress and/or expression of Fas ligand in neurons and glia 
85
. Alternatively, microglia can be activated, 
promoting TNFα secretion and activation of the TNFR-mediated extrinsic apoptotic pathway 86,87. Importantly, 
the use of antioxidants intended to suppress lipid peroxidation and compounds known to stabilize calcium 
homeostasis were shown to protect neurons against Aβ-induced apoptosis 88. Additional evidences 
demonstrating the involvement of apoptotic cascades in AD pathology also include the observation that APP 
may function as a substrate for caspase-3 
89
.  
It deserves to mention that an increasingly proposed alternative, crucial subcellular regulator of 
apoptosis (particularly in AD) is endoplasmic reticulum (ER) 
78. This organelle’s role in apoptosis propably 
involves mitochondria sensitization to a variety of extrinsic and intrinsic death stimuli and/or its own initiating 
cell death signals 
90
.  Interestingly, several evidences showed the direction of proteins from all Bcl-2 classes 
towards the ER 
78
 and although the underlying mechanisms are still poorly understood, it is plausible that ER 
stress-associated apoptosis may involve disturbed glycosylation, misfolded proteins (as in glucose deprivation 
impairment in unfolded protein response), cytoplasmic death pathways induced by the mobilization of ER 
calcium stores, sensitization of mitochondria to respond to direct proapoptotic stimuli 
65
. This in turn would lead 
to caspase-12 activation and possible direct processing of  downstream cytosolic caspases 
91
. Despite some 
controversy, authors suggested that active caspase-12 was able to cleave and activate procaspase-9 directly, then 
resulting in downstream caspase-3 activation 
92,93
.  Although caspase-12 is a ubiquitously expressed enzyme, 
being synthesized as an inactive procaspase composed by a regulatory prodomain and two catalytic p20 and p10 
subunits 
94
, its unique feature is its almost exclusive activation by insults that bring forth ER stress 
92
. Therefore, 
caspase-12 activation rendered it a useful marker for ER stress-related apoptosis. After ER stress, this organelle 
tries to reestablish homeostasis by activating the unfolded protein response (UPR), aiming at protecting and 
triggering adaptive pathways 
95
. Nonetheless, chronically activated UPR may also have negative effects on cell 
survival, as it affects the folding and trafficking of proteins and has been suggested to play a role in 
neurodegenerative diseases, including AD 
96
. Indeed, it has been hypothesized that ER stress may interfere with 
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the trafficking and processing of APP during the secretory pathway, leading to an intracellular overproduction 
of Aβ and consequent oxidative stress that may culminate in apoptotic cell death in AD 97. 
 
b) Necrosis  
Another type of cell death that has been increasingly described is necrosis. Together with apoptosis and 
autophagy, necrosis contributes for the maintenance of homeostasis in multicellular organisms, by keeping the 
balance between cell proliferation and cell death 
63
. Necrosis is a highly regulated and programmed event, 
sharing a variety of components with other types of cell death 
98
. Morphologically, necrosis is characterized by 
a rapid cytoplasmic swelling that culminates in plasma membrane rupture and organelle breakdown 
99
. 
Traditionally, necrosis was faced as a consequence of severe physical and/or chemical stress factors (e.g. heat, 
osmotic shock, mechanical stress, freeze/thawing and high concentrations of hydrogen peroxide) 
63
.  
Molecularly, receptor-interacting proteins 1 and 3 (RIP1 and RIP3, respectively) seem to be critical inducers of 
programmed necrosis (Fig. 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Potential mechanisms of RIP3/RIP1-mediated necrosis. In cells depleted from RIP3, TNF induces apoptosis 
independently from this protein; however, when RIP3 is sufficiently expressed, TNF stimulation opens the gateways to 
use glutamate (Glu) or glutamine (Gln). As a consequence of such abnormal metabolic stimulation, reactive oxygen 
species (ROS) levels may rise, mostly due to the mitochondrial respiration chain, initiating the alterations typical from 
necrosis cell death. Abbreviations: FADD, Fas-associated death domain; GLUL, glutamate ammonia ligase; RIP, 
receptor-interacting protein; ROS, reactive oxygen species; TCA, tricarboxylic acid cycle; TNF, tumor-necrosis factor; 
TNF-R1, tumor-necrosis factor receptor 1; TRADD, TNF-receptor-associated death domain; TRAF, TNF-receptor-
associated factor. [Adapted from Zhang et al, 2010]. 
 
These proteins belong to the RIP kinase family, whose members have different functional domains, 
despite sharing a homologous kinase domain 
100
. More specifically, RIP1 contains a C-terminal death domain 
that allows it to be recruited to various complexes, which will initiate different signaling pathways 
101
. 
Conversely, RIP3 has a C-terminus that is unique among all known protein domains. Besides this, it was also 
11 
 
found a RIP homotypic interaction motif (RHIM) in the intermediate domain of RIP1 and in the C-terminus of 
RIP3, that appears to be necessary for the interaction between both proteins 
102
. Interestingly, RIP1 is known to 
be also involved in several signaling pathways and play other numerous roles than necrosis, being referred to as 
a key switch of cell fate regulation 
103
, as it is able to direct the cell to an apoptotic cell death instead of a 
necrotic one 
104
. Additionally, RIP1 mediates the activation of the prosurvival transcription factor nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB) 
105
. On the other hand, Cho et al. (2009) reported that 
RIP1 phosphorylation upon necrosis was regulated by RIP3, suggesting that the later one may be the central 
controller of programmed necrosis, by initiating the pronecrotic kinase cascade 
105
. In the brain, RIP1 and RIP3 
have been implicated as part of the necrosome complex that leads to programmed necrosis after neonatal 
hypoxic injury 
98
. Additionally, it has been suggested that the loss of hypoccampal neurons occurring during the 
initiation and progression phases of AD could also involve cytokine-driven neuroinflammation and 
neurotoxicity, whereby TNF appeared to be a key proinfammatory cytokine 106. In line with this, RIP3-
mediated necroptosis (regulated necrosis) was shown to be activated in mouse hippocampus after 
intracerebroventricular injection of TNF-α, whilst RIP3 deficiency attenuated the loss of hippocampal neurons 
due to TNF-α 107. 
 
1.1.2. Endogenous insulin/insulin receptor signaling as the missing link between T2D and AD 
 
1.1.2.1. The role of endogenous insulin in normal brain 
Traditionally, insulin was recognized as a crucial regulator of peripheral glucose metabolism, 
particularly in fat, liver or muscles. However, recent evidences showed that, besides reaching high levels in 
CNS, the hormone is also able to control several brain functions 
108
. These include cognitive function, memory, 
learning and synaptic plasticity,  most likely via the activation of insulin/insulin receptor (IR) signaling 
pathways 
109
. Regarding its origin, it is believed that most CNS insulin derives primarily  from pancreatic β-
cells, being transported mostly across the BBB 
110
. Additionally, some of the peripherally-synthesized insulin 
may also directly diffuse into the CNS via a circumventricular region with a “leaky” BBB - the area postrema 
111
. However, some striking data also point towards the de novo brain insulin synthesis, particularly in 
pyramidal neurons (e.g., from hippocampus, prefrontal cortex and olfactory bulb, but not glial cells), being then 
exocytotically released 
17
. Once in CNS, insulin rapidly binds to its highly abundant and ubiquitously 
distributed specific receptor (with a particular emphasis on olfactory bulb, hypothalamus, cerebral cortex, 
cerebellum, hippocampus and striatum)
112
, initiating its signal transduction 
110
. 
 
1.1.2.2. Brain insulin/IR dysfunction in T2D and AD 
Several lines of evidence suggest that the T2D-associated impairment in brain insulin uptake may 
deprive this tissue from the peptide’s beneficial effects 108. In this perspective, whilst acutely increased 
peripheral insulin levels may transiently increase its levels in cerebrospinal fluid, the insulin resistance- or T2D-
related peripheral hyperinsulinemia may chronically downregulate IRs at BBB, impairing brain insulin uptake 
110
 and ultimately affecting learning, memory and cognition 
112–114
. Therefore, it has been increasingly proposed 
that dysfunctional insulin/IR-mediated signaling might constitute the missing link between diabetes 
(particularly T2D) and AD 
115
. This has been further supported by the hormone’s role in the regulation of Aβ 
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deposition and tau hyperphosphorylation (the main neuropathological hallmarks of AD) 
116
. More specifically, 
insulin/IR dysfunction has been associated with abnormal tau protein hyperphosphorylation, reduced APP 
processing and impaired Aβ release for extraneuronal clearance, thereby promoting the abnormal Aβ 
accumulation inside neurons 
110
. Additionally, under hyperinsulinemic conditions, the insulin in excess 
competes with Aβ for insulin-degrading enzyme (IDE, a metalloprotease that degrades both insulin and Aβ), 
resulting in abnormal Aβ accumulation and formation of senile plaques 117. Besides this, Ho et al. (2004) 118 
observed that a diet-induced insulin resistance and a hyperinsulinemic state in an AD-like model decreased IDE 
levels and Aβ accumulation, whilst rosiglitazone (an insulin sensitizer) administration reduced Aβ1-42 levels (the 
main pathological form of Aβ in brain tissues) and improved learning and memory119. These results suggested 
that the restoration of insulin signaling (as with rosiglitazone) and the subsequent decrement in the hormone 
available could limit its competition with Aβ, thus allowing the peptide degradation by IDE 119.  
Interestingly, previous studies in our group showed that insulin may exert a neuroprotective role against 
oxidative stress 
120,121
. Indeed, exogenously added insulin was able to activate neuronal IR/IGF-1 receptor (IGF-
1R)-mediated signaling pathways upon oxidative stress, thereby promoting PI3K- and extracellular-signal-
regulated kinases (ERK) 1/2-mediated signaling and inhibiting glycogen synthase kinase-3beta (GSK-3β). As a 
result, neurons were protected against neuronal lipid and protein oxidation, particularly against the formation of 
4-hydroxynonenal (4-HNE, a byproduct of oxidation) adducts on neuronal GLUT3 glucose transporters 
120
. 
This was accompanied by a stimulation of neuronal glucose uptake and downstream metabolization into 
pyruvate, thereby leading to an overall increase in neuronal energy levels, preventing both necrotic and 
apoptotic neuronal death and restoring neuronal viability 
122
. These results were in accordance with the insulin-
mediated activation of mitogen-activated protein kinase (MAPK) signaling (namely p38 MAPK) and the 
subsequent suppression of caspase-3 activity, that besides protecting against neuronal apoptosis could also play 
a role in memory and learning 
109
. Interestingly, we also reported that, under T2D and/or oxidative stress, 
insulin was able to modulate the transport of the amino acid neurotransmitters -aminobutyric acid (GABA) and 
glutamate
121,123,124
. 
Besides insulin, IGF-1 and -2 and relaxin also share structural similarities and belong to the same protein 
family 
125
. Importantly, IGF-1 also crosses the BBB and is ubiquitously distributed in rodent and human brains, 
having several pivotal effects in CNS 
126,127
. Therefore, it is not surprising that, similarly to insulin/IR, IGF-
1/IGF-1R-mediated signaling also regulate brain glucose metabolism, neuronal growth and differentiation, 
neuromodulation, synaptic transmission, memory/learning and neuroprotection 
17
. Accordingly, several studies 
reported that impaired insulin and IGF-1 signaling in T2D models were accompanied by neuronal loss, neurite 
degeneration, APP dysmetabolism and tau protein hyperphosphorylation 
126,128
.  
 
1.2. Could anti-T2D therapies be also promising against AD? 
 
1.2.1. The main therapeutic goals in T2D management 
From the above, it seems unquestionable that T2D and AD are two intrinsically related pathologies with 
several common mechanisms. Therefore, it has been increasingly proposed that an anti-T2D treatment could be 
also beneficial against AD (Fig. 1.3) and, thus, the use of anti-T2D drugs (already in clinical use or under 
clinical trials) in the context of AD has been deeply and increasingly explored in the recent years 
129
.  
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Regarding T2D and its chronic complications’ management, it is widely accepted that, at least in the 
initial phases of the disease, maintenance of blood glucose levels within the normal range constitutes a highly 
efficient approach to reduce the risk of such long-term vascular and cardiovascular complications. Nevertheless, 
as T2D progresses, this first approach may lose efficiency and then its successful management may also include 
the control of blood pressure and lipid levels 
130
. Thus, we must bear in mind that, although the main goal of 
diabetes therapy relies on an optimal glycemic control (Fig. 1.3), in the long run this may not be enough to 
reduce the cardiovascular risk 
131
. Additionally, recent outcomes from clinical trials (as the Action in Diabetes 
and Vascular disease: preterAx and diamicroNmr Controlled Evaluation (ADVANCE), Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) and Veterans Affairs Diabetes Trial (VADT)) led to a new 
guideline on the consideration of specific patient/disease factors when prescribing a patient-adjusted therapeutic 
strategy against hyperglycemia 
132
. 
Moreover, besides the achievement of euglycemia, efficient T2D therapeutic approaches should also aim 
at decreasing glycosylated hemoglogin A1C (HbA1C) (Fig. 1.3) 
133
, whose levels provide an indirect estimation 
on the average plasma glucose levels in the last 2-3 months, thus giving an idea on the “long- term” (rather than 
“acute”) control of blood glucose levels 134. However, some controversy still remains on the ideal HbA1C levels. 
Importantly, several studies reported that lowering HbA1C levels by 1% reduced microvascular complications 
by ~30%, as well as the risk for myocardial infarction and death from any cause after 10 years of intensive 
glucose control in newly diagnosed T2D patients 
135
. In this perspective, the guidelines suggest that an 
appropriate anti-T2D therapeutic should also consider the initial values of HbA1C 
136
. However, as most oral 
anti-hyperglycemic agents can reduce HbA1C by 1.5-2.0% from baseline levels of 8.5- 9.5%, this means that a 
patient with a baseline HbA1C level higher than 9% will probably experience some difficulties in achieving a 
therapeutic goal of less than 7.0% and, therefore, may require a combination therapy in a near future 
131
.  
It is also well accepted that T2D treatment should also aim at the reduction in insulin resistance (e.g. 
with diet, exercise, and/or drug therapy) and/or the stimulation in insulin secretion (Fig. 1.3)
137
. Therefore, it is 
not surprising that, in the later stages of disease, T2D patients may also need insulin injections 
9
. However, as 
discussed later, these may have the inconvenient of repeated insulin-induced hypoglycemic episodes and, for 
this reason, several promising drugs are being tested to better address T2D pathogenesis and to overcome the 
risk for hypoglycemia and/or other associated risk factors (as obesity). In this perspective, as obesity is one of 
the risk factors closely related with T2D progression and the development of late complications, guidelines also 
refer that patient’s body weight should be also taken into account in the chosen therapeutic strategy 138. Notably, 
this might be even more relevant given that body weight gain is a frequent secondary effect of some anti-
diabetes therapies 
138
. For this reason, recently developed drugs also have into account their effects on 
adipogenesis and fat mass regulation 
139
. 
From the several classes of anti-T2D compounds already in clinical use (e.g. biguanides, sulphonylureas, 
thiazolidinediones), we will next give an overview on the pros and cons of insulin and incretin-based agents 
(especially exendin-4) as potential therapeutic approaches against AD. 
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Figure 1.3. Effects of several anti-diabetic agents in the crosstalk between peripheral system and CNS. Some of 
available anti-T2D classes of drugs include biguanides, sulphonylureas (SUs), thiazolidinediones (TZDs) and the more 
recent incretin-based therapies, dipeptidylpeptidase-IV (DPP-IV) inhibitors and glucagon-like peptide-1 (GLP-1) receptor 
(GLP-1R) agonists. Some of the main goals in T2D management include the decrement in hyperglycemia, HbA1C and 
total cholesterol levels. Additionally, both the reduction in insulin resistance and restoration of insulin secretion have been 
increasingly faced as a highly relevant goal. This might be even more crucial given that insulin/IR signaling dysfunction is 
a common feature to both T2D and AD. Therefore, anti-T2D therapies may also benefit the CNS by, e.g., counteracting 
oxidative stress, mitochondrial dysfunction and neuronal death, and/or by stimulation of neurogenesis and synaptic 
function. Noteworthy, some of these anti-T2D compounds were also reported to reduce Aβ accumulation and tau protein 
hyperphosphorylation, thus suggesting a potential beneficial impact against AD [Adapted from Sebastião et al. 
(unpublished)]. 
 
1.2.2. Exogenously-administered insulin as an anti-T2D and anti-AD therapy: the pros and cons 
Traditionally, peripherally-administered insulin has been used as an anti-T1D therapy, aiming at 
controlling blood glucose levels and preventing its chronic complications 
132,140
. But, as previously mentioned, 
it has been also increasingly used in T2D patients, particularly in the later stages of disease, when anti-
hyperglycemic agents are no longer efficient. However, the frequent hypoglycemia episodes occurring after 
insulin therapy 
131
 have been also increasingly described to negatively affect the hippocampus, external cortical 
layers and striatum, leading to neuronal death and subsequent memory, learning and other neurological deficits, 
seizures and eventually coma 
141,142
. In this perspective, our group has recently demonstrated that insulin-
induced hypoglycemia leads to brain mitochondrial dysfunction and increased oxidative stress 
22,143
. Moreover, 
plasma aspartate, glutamate, glutamine and taurine levels increased, whereas GABA levels decreased after an 
acute episode of insulin-induced hypoglycemia in rats 
140
. Under similar conditions, rat brain cortical 
synaptosomes displayed higher glutamate and taurine levels, while GABA was decreased 
140
. Additionally, the 
release of the excitatory amino acids aspartate, glutamate and taurine from hypoglycemic synaptosomes was 
further exacerbated by depolarization, thereby suggesting a possible mechanism by which an additional 
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metabolic insult may underlie the neuronal injury and degeneration, as well as the cognitive impairment often 
associated with diabetes 
140
. 
Despite these limitations posed by exogenous insulin therapy, we must be aware that, as previously 
described, insulin (particularly the endogenous one) has been also widely recognized as a crucial hormone for 
the CNS. And given the ubiquitous localization of IRs in hippocampus, and entorhinal and frontal cortices, 
together with its expression primarily at the synapses, it is not surprising that physiological IR-mediated 
signaling may contribute to synaptic remodeling and memory formation 
144
. Furthermore, insulin’s benefits in 
brain also include the modulation of Aβ formation/clearance, thereby protecting against its detrimental effects 
on synapses 
128
, as detailed in section 1.1.2. 
 
1.2.3. Incretin-based anti-T2D drugs: GLP-1 receptor agonists and DPP-IV inhibitors 
Incretins were discovered in the 1960s, after the increase in insulin secretion induced by a glucose load 
130,145,146
. This effect was due to the simultaneous action of two gastrointestinal hormones: GLP-1 (an incretin of 
30 amino acid length, secreted by the enteroendocrine K cells) and glucose-dependent insulinotropic 
polypeptide (or gastric inhibitory polypeptide (GIP), secreted by the enteroendocrine L cells) 
130,146
. More 
recently, it has been shown that the two hormones combined not only account for about 70% of the insulin 
response to glucose 
1
, but they also stimulate insulin synthesis and secretion 
146
. The earliest endocrine 
metabolism activated after a meal is the insulinotropic incretin effect that consists on the activation of the potent 
insulinotropic GLP-1 immediately after GIP secretion and despite the controversy on the underlying 
mechanism, it is possible that both central and peripheral actions of GLP-1 may stimulate insulin and inhibit 
glucagon secretion to restore the normal blood glucose levels 
1,146,147
 reduce gastric emptying, appetite, food 
intake and body weight 
132,146,148–150
.  Together with these peripheral effects, both GIP and GLP-1 can bind and 
activate structurally distinct G-protein coupled receptors (GPCRs) 
111
, with GIP receptor being predominantly 
expressed on islet β-cells and (to a lesser extent) in CNS and in adipose tissue, whereas GLP-1 receptor (GLP-
1R) is expressed in islet α and β cells, central and peripheral nervous systems, heart, kidney, lung, and 
gastrointestinal tract 
111
.   Physiological activation of GLP-1R-mediated aerobic metabolization of glucose 
via glycolysis and the subsequent rising in cytosolic ATP levels have been described to close the 
hyperpolarizing ATP-dependent potassium (KATP) channels, depolarizing pancreatic -cells and allowing 
calcium influx through voltage-dependent calcium channels (VDCC), with the concomitant calcium-dependent 
insulin exocytosis 
148,149,151
 (Fig. 1.4). However, insulin secretion may be also stimulated by other intracellular 
signalling cascades involving, e.g., cAMP or its downstream target Epac (Exchange protein cAMP), protein 
kinase A (PKA), AMPK, protein kinase C (PKC) and MAPK 
111,131,146,151,152
. Once blood glucose levels return 
to normal, GLP-1-induced insulin exocytosis is decreased 
131,146
 (Fig. 1.4). 
 Notably, several lines of evidence point towards a simultaneous CNS-mediated intervention on 
peripheral GLP-1-induced glucoregulation 
1,146
. And, as discussed below  (Section 1.2.4), an increasing body of 
literature has been suggesting that anti-T2D drugs from the classes of GLP-1 analogues and 
dipeptidylpeptidase-IV (DPP-IV) inhibitors may also constitute promising therapeutic strategies against chronic 
T2D complications affecting the CNS, particularly dementia and AD. 
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Figure 1.4. Mechanisms of first phase of insulin secretion by GLP-1 mimetics. GLP-1 and GLP-1R agonists exert their 
actions by binding to GLP-1R, a G-protein coupled receptor (GPCR). GLP-1R is ubiquitously expressed throughout the 
whole body, including peripheral and central nervous systems. Despite some controversy, it has been hypothesized that 
incretin receptor activation in β-cells after a meal leads to glucose metabolization through glycolysis and the subsequent 
increase in cytosolic ATP content. Then, the hyperpolarizing KATP channels close and -cell membrane depolarizes, 
allowing calcium influx to occur via the voltage-dependent calcium channels (VDCC) and culminating in calcium-
dependent insulin exocytosis. Alternatively, insulin secretion may be also stimulated by intracellular signalling cascades 
involving, e.g., cyclic AMP (cAMP) or its downstream targets Epac (Exchange protein activated by cAMP), protein 
kinase A (PKA), AMP kinase (AMPK), protein kinase C (PKC) or MAPK. As blood glucose levels return to normal, 
GLP-1-induced insulin exocytosis is decreased. [Adapted from Sebastião et al. (unpublished)]. 
 
Despite such apparent efficiency, due to its almost complete degradation by DPP-IV (an ubiquituously 
expressed aminopeptidase that occurs, e.g., in liver, lung, kidney, endothelium and lymphocytes)
153
, human 
endogenous GLP-1 actions are highly limited due to its very short half-life (1-2 minutes) 
154
. And, as this 
rendered the therapeutic use of the naturally-occurring human GLP-1 highly unfeasible, several long-acting 
GLP-1R agonists have been developed in the recent years to treat T2D, with the advantage of 1) mimicking the 
endogenous GLP-1 effects and 2) being more resistant to DPP-IV-mediated degradation 
155
. In fact, mice with 
targeted downregulation of DPP-IV were described to have increased plasma GIP and GLP-1 levels, as well as 
insulin exocytosis, which were accompanied by a lower glucose release
156
. Importantly herein, several clinical 
studies described that exenatide or liraglutide (two GLP-1R agonists currently used in T2D treatment) were 
more efficient in decreasing blood glucose levels in hyperglycemic T2D patients than sitagliptin (a DPP-IV 
inhibitor) 
1,157
, with the additional advantage of minimizing the risk of hypoglycemia and weight gain (in 
comparison with insulin and other oral anti-T2D drugs)
1
. Moreover, GLP-1R agonists appeared to restore β-cell 
function, a highly relevant issue, as frequently (by the time of T2D diagnosis) β-cell mass and function are 
already impaired
1
. However, these compounds are not free from some secondary effects, with some patients 
treated with exenatide reporting nausea, diarrhea 
146,158
 and, although controversial, pancreatitis 
159
. 
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Regarding DPP-IV inhibitors, clinical studies described their good tolerability, the advantages on their 
oral intake (instead of peripheral injection, as GLP-1R agonists) 
131
 and, despite their neutrality on body weight 
and gastric emptying, they lower fasting and postprandial glucose 
160
, as well as HbA1C levels in T2D patients 
that simultaneously undergo metformin administration 
161
. Besides incretins, other DPP-IV substrates include 
other gastrointestinal hormones, neuropeptides, cytokines and chemokines 
146
. Amongst them, the neuropeptide 
Y (NPY) is widely known to affect lipid metabolism and adipogenesis and blockade of its receptor was shown 
to blunt the DPP-IV-mediated stimulation of lipid accumulation 
139
. Amongst DPP-IV inhibitors, sitagliptin, 
saxagliptin and linagliptin have been approved by the Food and Drug Administration (FDA) for treatment of 
T2D patients, whereas vildagliptin is also available in the European Union and alogliptin in Japan 
132
. At their 
recommended doses, a daily administration of these DPP-IV inhibitors was shown to blunt DPP-IV activity for 
at least 24 h (except vildagliptin, which required a twice daily administration) 
162
. Additionally, DPP-IV 
inhibitors can be used either as monotherapy or together with other oral agents or insulin and they induced low 
overall hypoglycemia rates (comparable to those of GLP-1R agonists)
132
. Importantly, as GLP-1 analogues, 
DPP-IV inhibitors also become less effective as insulin resistance progresses and pancreatic β-cells function 
deteriorates 
155
. 
 
1.2.4. GLP-1 mimetics and GLP-1R agonists as potentially efficient drugs against neurodegeneration 
and AD  
It is widely known that GLP-1 is also ubiquitously expressed in CNS, especially in cortex, hippocampus, 
hypothalamus, striatum, substantia nigra, brain stem and subventricular zone (an area of adult brain 
neurogenesis) 
155
. Therefore, it is not surprising that not only the main peripheral roles of GLP-1 might be 
centrally controlled, but also that this incretin may play a pivotal role in CNS. Moreover, as brain GLP-1 has 
been increasingly faced as a neuroprotective molecule, its receptors at CNS may represent promising targets 
against neurodegeneration/death and learning/memory disturbances, ie, a putative pharmacological strategy 
against age- and/or T2D-related neurodegenerative diseases may necessarily involve GLP-1R. Accordingly, 
During et al. (2003) 
163
 reported that knockout mice for GLP-1R had memory and learning deficits. 
 
 1.2.4.1. GLP-1 mimetics: liraglutide  
Amongst the already marketed GLP-1 analogs, liraglutide is the main long-acting compound, being used 
either as a monotherapy or in combination with metformin or thiazolidinediones (TZDs)
132
. Structurally, 
liraglutide shares 96% similarity with human GLP-1 and, when combined with sulphonylureas (SUs), decreases 
the risk for hypoglycemia 
132
. Importantly, liraglutide-induced prevention in hippocampal synaptic loss was 
accompanied by restoration of synaptic plasticity and memory function in the APP/PS1 mouse model of AD 
164
. 
Additionally, liraglutide decreased the formation of Aβ plaques165 and the inflammatory response (by activating 
less astrocytes and microglia) 
166
, and promoted neurogenesis/neuronal proliferation in dentate gyrus 
167
. 
Although these results point towards the beneficial use of liraglutide as an anti-AD pharmacological approach, 
further clarifying research is needed, with a particular emphasis on the ongoing clinical trials (NCT01469351 
and NCT01843075, according to www.clinicaltrials.gov). 
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Given all the interesting features of incretin hormone’s analogues (particularly their uniqueness of 
promoting a glucose-dependent insulin secretion, minimizing the damage associated with repeated 
hypoglycemia episodes), intense research efforts have been done in the recent years to develop and test other 
similar drugs, that may also represent some neuroprotective potential, as described elsewhere.  
 
 
1.2.4.2. GLP-1R agonists: exendin-4, lixisenatide and albiglutide 
Besides GLP-1 analogues (as liraglutide), the incretin class of anti-T2D drugs also include the GLP-1R 
agonists. Amongst the novel GLP-1R agonists, lixisenatide and albiglutide are currently undergoing phase III 
trials. Lixisenatide is based on exendin-4(1–39), with a modified C-terminal containing six additional lysine 
residues that not only increase its affinity to GLP-1R by 4-fold compared to the human GLP-1, but also extends 
its half-life to 3h 
168,169
. Importantly, lixisenatide was already shown to cross the BBB into the CNS, thereby 
preventing Aβ-related impaired synaptic plasticity, hippocampal long-term potentiation (LTP) and spatial 
learning and memory deficits, most likely via the PI3K/Akt/GSK3β pathway 170. Additionally, lixisenatide has 
been described to exert strong neurogenic effects in an AD rodent model 
167,171
. 
Albiglutide consists of two GLP-1(7–36) molecules connected to recombinant human albumin172, with a 
single amino acid substitution (ala→ gly) that renders it resistant to DPP-IV and with a half-life of ~5 days 
(which allows for a weekly dosing) 
173
. Unfortunately, its size renders albiglutide unable to cross the BBB, also 
affecting its potential in body weight reduction and gastrointestinal tolerability
174
. Its secondary effects include 
nausea and injection site reactions 
132
.  
Importantly herein, one of the most widely clinically used and best studied incretin-based therapy is 
exenatide (exendin-4, Ex-4), whose high efficiency against T2D and CNS damage have been increasingly 
demonstrated  
175
. Exenatide is a synthetic, injectable GLP-1R agonist derived from Ex-4, a peptide obtained 
from the saliva of the Gila monster (Heloderma suspectum), being also resistant to DPP-IV 
176
. Although Ex-4 
only shares only a 53% amino acid sequence homology with human GLP-1, its effectiveness in lowering 
glucose levels is by far higher 
146
. Therapeutically, Ex-4 may constitute an important supplement to diet and 
exercise in improving glycemic control in T2D adults 
1
, either as a monotherapy or in combination with other 
oral agents 
177
. Ex-4 also reduces HbA1C levels by 0.8–0.9%, decreases food intake 
178
 and, together with 
metformin and/or SUs, was shown to reduce body weight
179
. Strikingly, exenatide was also shown to promote 
graft survival and function in newly islet-cell transplanted T1D patients 
180
. Although the underlying 
mechanisms remain poorly understood, it is plausible that, similarly to endogenous GLP-1, Ex-4 binds to (and 
activates) GLP-1R on pancreatic β-cells, thereby activating adenyl cyclase and rapidly increasing cAMP levels, 
with the subsequent stimulation of intracellular signaling cascades 
111
 that may culminate in the modulation of 
pancreatic β-cells’ proliferation and function, together with an inhibition of apoptosis 146,147,178. It is plausible 
that these actions of Ex-4 may occur together with its potent effects on glucose-dependent insulin secretion and 
insulin gene expression 
181
. Nevertheless, some transient nausea and occasional vomiting have been frequently 
reported as Ex-4 side effects
182
.  
Regarding its effects on CNS, it has been shown that Ex-4’s stability in blood (being insensitive to food 
deprivation for 24h
183
) and high lipophilicity allowed most of the peripherally-injected Ex-4 to cross the BBB 
without being trapped by its endothelial cells, thus rapidly reaching the brain intact 
147
. Besides this, the 
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ubiquitous GLP-1R expression in CNS 
184
 further suggests that its activation and the downstream signaling 
cascades may at least partially be involved in Ex-4-mediated stimulation of neurogenesis in subventricular zone 
185
, neurite outgrowth, neuronal differentiation, rescue of degenerating neuronal cells and protection against 
both in vitro and in vivo excitotoxic damage 
186
. Ex-4 also improved hippocampus-associated behavior in adult 
rodents 
187
 and protected against neuroinflammation 
158
. More strikingly, Ex-4 was described to protect against 
Aβ-associated hippocampal neuronal death and rescue learning and memory in intracerebroventricularly-
injected streptozotocin rats (a model of sporadic AD) 
1
. In this perspective, besides its already proven important 
clinical impact against T2D, Ex-4 (or even other incretins) could also constitute a promising therapeutic strategy 
against AD, with the some expectation existing on the results from the ongoing clinical trial (NCT01255163, 
according to www.clinicaltrials.gov). 
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2. HYPOTHESIS AND AIMS 
 
From the above, we hypothesized that Ex-4 restores the T2D-associated alterations in intracellular 
quality control mechanisms, neurodegeneration and death, thereby improving synaptic function and, ultimately, 
cognitive function. 
Therefore, our main goal was to analyze the potential neuroprotective effect of chronic, continuous 
peripheral Ex-4 administration in middle-aged T2D rat brain. In this perspective, we analyzed the effect of 
chronic peripheral Ex-4 treatment in T2D: 1) pathological features (glycemia, rate of glucose clearance from 
blood, plasma insulin levels and insulin resistance, HbA1C levels); 2) other T2D-associated risk factors (as body 
weight, hypercholesterolemia, hypertriglyceridemia and high blood pressure), as well as in 3) rat brain cortical 
markers of oxidative stress, 4) synaptic (dys)function, 5) cellular quality control (autophagic) mechanisms and 
6) neurodegeneration and caspase-dependent and –independent apoptotic and necrotic cellular death.  
Since long ago, rodent models have been the preferred and most widely used animal models of human 
pathologies, being regularly used to study neurological pathogenic mechanisms (due to the several similarities 
with human brains) and the overall effects of experimental therapies aiming at preventing or curing such 
diseases. Herewith, we used middle-aged (8 month old) non-diabetic male Wistar and T2D Goto-Kakizaki (GK) 
rat brain cortical homogenates, either submitted or not to the continuous peripheral delivery of the GLP-1R 
agonist Ex-4, for 28 days. GK rats are one of the most well known rodent models of T2D 
188
, resulting from the 
selective breeding of Wistar rats with oral glucose intolerance 
189
. GK rats develop oral glucose intolerance as 
early as 2 weeks of age, exhibiting elevated plasma glucose levels upon administration of a glucose load at 4 
weeks of age. By the 12 weeks of age, GK rats exhibited a T2D profile, characterized by elevated fasting 
glucose and insulin levels and a prolonged elevation in plasma glucose levels after an oral glucose load 
188
. 
Since these animals are non-obese and spontaneously T2D, displaying also a defective insulin action and long-
term complications similarly to those occurring in T2D humans 
190
, we strongly believe that they may constitute 
a highly valuable model to analyze the chronic effects of T2D per se on CNS, without the interference of other 
risk factors (e.g. obesity, hypertension). 
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2.1. Materials 
Micro osmotic Alzet 2ML4 pumps were from Durect Corporation (Cupertino, CA, USA). Commercial 
glucometer (Glucometer-Elite) and compatible reactive tests (Ascencia Elite), as well as the A1C Now HbA1C 
Multi-Test were purchased to Bayer (Portugal). Rat Insulin EIA Kit was from SPI-BIO, Bertin Pharma 
(Montigny le Bretonneux, France). LE 5001 Non Invasive Blood Pressure meter was obtained from Panlab, 
Harvard Apparatus (Holliston, Massachusetts, USA). Accutrend kit for cholesterol and triglycerides and 
compatible stripes, PhosSTOP Phosphatase Inhibitor Cocktail Tablets and Complete, Mini, EDTA-free Protease 
Inhibitor Cocktail Tablets in easy packs were from Roche Diagnostics (Portugal). Rat GLP-1 ELISA kit was 
bought to Elabscience Biotechnology Co.,Ltd (Wuhan, China). QuantiChrom Glucose Assay Kit was from 
BioAssay Systems (Hayward, CA, USA). Polyvinylidene difluoride (PVDF) membranes (Immobilon®-P 
PVDF transfer membranes 0,45 μm) were purchased to Merck-Millipore (Germany). protease from Bacillus 
licheniformis (Type VIII), rabbit polyclonal anti-LC3 antibody, mouse monoclonal anti-synaptophysin, mouse 
monoclonal anti-actin, caspases-1 (N-acetyl-Tyr-Val-Ala-Asp-P-nitroanilide, Ac-YVAD-pNA) and -2 (N-
acetyl-Val-Asp-Ala-Val-P-nitroanilide, Ac-VDAV-pNA) were from Sigma (USA). Ex-4 (Exenatide), mouse 
monoclonal anti-beclin 1, rabbit polyclonal anti-RIP1, rabbit polyclonal anti-RIP3 and rabbit polyclonal anti-
GLP-1R were all from Abcam (Cambridge, UK). Rabbit polyclonal anti-P-mTOR antibody, mouse monoclonal 
anti-mTOR, rabbit monoclonal anti-PI3K class III, rabbit polyclonal anti-BAX and anti-Bcl2, rabbit polyclonal 
anti-caspase 12, rabbit monoclonal anti-PSD-95 and rabbit monoclonal anti-α-tubulin were purchased to Cell 
Signaling (The Netherlands). Mouse monoclonal anti-cytochrome c was from BD Pharmingen (San Diego, CA, 
USA). Anti-rabbit and anti-mouse IgG secondary antibodies and ECF fluorescence reagent were from GE 
Healthcare (Piscataway, NJ, USA). Protein A PLUS-Agarose Immunoprecipitation Reagent and rabbit 
polyclonal anti-TOM20 was from Santa Cruz Biotechnology (Dallas, Texas, USA). 8-Hydroxy-2-deoxy 
Guanosine EIA kit was obtained from Cayman Chemical (Pittsburgh, USA). Colorimetric substrates for 
caspases-3 (N-acetyl-Asp-Glu-Val-Asp-P-nitroanilide, Ac-DEVD-pNA), -8 (N-acetyl-Ile-Glu-Thr-Asp-P-
nitroanilide, Ac-IETD-pNA) and -9 (N-acetyl-Leu-Glu-His-Asp-P-nitroanilide, Ac-LEHD-pNA) were 
purchased to Calbiochem (Darmstadt, Germany). All other reagents were of the highest grade of purity 
commercially available. 
2.2. Animal characterization 
Following Directive 2010/63/EU, Portuguese legislation and ethical approval provided by our 
institution’s ethical committee, all efforts were made to reduce the number of animals used and to minimize 
animal suffering. Therefore, thirteen non-diabetic male Wistar rats (controls) of sixteen weeks old, obtained 
from Charles River (Barcelona, Spain), and twenty-six male, spontaneously T2D GK rats of sixteen weeks old, 
from Taconic Europe (Lille Skensved, Denmark) were housed in our Animal Research Center Laboratory 
(Faculty of Medicine/Center for Neuroscience and Cell Biology, University of Coimbra), under controlled light 
(12 h day/night cycle) and humidity conditions, and with free access to powdered rodent diet (Diet 4RF21 GLP, 
Mucedola Srl, Settimo Milanese, Italy) and water. After one month quarantine and adaptation period, animals’ 
welfare, signs of distress and T2D parameters were periodically monitored, and glucose tolerance tests were 
used as selection index.  
At 8 months old and before the treatment started, both Wistar and GK rats were physically characterized 
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(body weight) and relevant blood parameters (as glycemia, HbA1C, blood pressure, glucose tolerance test 
(GTT), insulin levels and HOMA-IR) were determined after a 6-hour fasting period during the morning. After a 
72h resting period, surgical implantation of micro osmotic pumps containing Ex-4 was performed, as described 
below.  
  
2.3. Peripheral surgical implantation of Ex-4-containing micro osmotic pumps 
All surgical procedures were performed under anesthesia with isofluorane atmosphere and local 
butorphanol injection. Briefly, thirteen Wistar rats and twenty-six GK rats were subcutaneously implanted with 
a micro osmotic pump, after a small incision in the skin between the scapulae 
191
, according to manufacturer's 
instructions. Rats were divided into three experimental groups. In one group (n=13), GK rats were continuously 
infused with Ex-4 (5 g/kg/day; infusion rate 2.5 l/h), for 28 days (from the 8th to 9th month of age)192. The 
remaining two groups (n=13 Wistar and n=13 GK rats) received saline infusion. Accuracy of micro osmotic 
pumps was verified according to manufacturer's instructions and also by weighing each pump before 
implantation and after removal from the animal.  
Treatment success and pump implantation safety involved a regular monitorization of body weight, 
relevant blood parameters (as glycemia, HbA1C, GTT, HOMA-IR, cholesterol, triglycerides), as well as blood 
“metabolic” hormones (e.g. insulin) (all these before and after treatment), thus ensuring that T2D hallmarks 
were not affected by pump implantation per se 
191,192
. At 9 months old (and after post-treatment in vivo 
monitorization and behavioral analysis), rats were euthanized under sodium pentobarbital anesthesia before 
sacrifice by cervical dislocation and decapitation (EU guideline 86/609/EEC). 
 
2.4. Body weight 
Body weight was monitored once/week, in early afternoon, from 8 months (pre-treatment) to 9 months 
of age (post-treatment) and results were expressed as body weight (g).  
 
2.5. Blood collection and plasma isolation 
Blood was collected either from caudal vein (in living, anesthetized rats), once/week (before, during and 
immediately after treatment), or directly from the heart by transcardial punction (immediately after animal's 
sacrifice) with a heparinized syringe. Plasma was obtained by centrifugation at 14 000 rpm, for 2 min, at 4 °C, 
in a 2-16PK Heated and Refrigerated Centrifuge (Sigma, Germany), to determine insulin levels and HOMA-IR. 
 
2.6. Blood glucose levels 
Blood glucose levels were determined by a glucose oxidase reaction, using a commercial glucometer 
and compatible reactive tests, before, during (once/week) and after treatment (from caudal vein blood), as well 
as immediately after animals’ sacrifice (intracardial punction blood). Results were expressed as mg glucose/dl 
blood. 
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2.7. GTT test 
GTT analyses the rate of glucose clearance from blood 
193
. Briefly, food was removed at about 8 a.m. 
(after nocturnal eating period) and rats were kept fasted for 6 h, being GTT test performed after 2 p.m. (resting 
period). Basal glycemia was measured before D-glucose injection, corresponding to time 0. Then, an 
intraperitoneal injection of 2 mg D-glucose/g body weight was given upon rat immobilization by the back of the 
neck and glycemia were determined after 15, 30, 60 and 120 min. At the end of the test, cages were supplied 
with wet food. Results were expressed as mg glucose/dl blood. 
 
2.8. HbA1C levels 
Glycosylated hemoglobin (HbA1C), an index of average glucose blood levels during the previous 2-3 
months, was measured once/month (before and after treatment) in blood from caudal vein, using the kit A1C 
Now Multi-Test with compatible reaction tests. Results were expressed as %. 
 
2.9. Plasma insulin levels and insulin resistance 
Plasma insulin levels were determined after treatment by using the Rat Insulin EIA Kit, according to 
manufacturer’s instructions. Briefly, this kit is based on the competition between unlabelled rat insulin and 
acetylcholinesterase (AChE) linked to rat insulin (tracer) for limited specific guinea-pig anti-rat insulin 
antiserum sites, which then bind to the goat anti-guinea pig antibody attached to the well. The AChE tracer 
reacts with the Ellman’s reagent forming a yellow compound, whose intensity is proportional to the amount of 
tracer bound to the well and inversely proportional to the content on free rat insulin. Thus, 100 l of EIA buffer 
was added to Non Specific Wells (NSB) and 50 ul to Maximum Binding (Bo) wells. Then, 25 l of each rat 
insulin standard and sample was added to the appropriate wells, followed by the addition of 25 l of rat insulin 
AChE tracer (except to the blanks). Finally, 25 l of rat insulin antiserum were dispensed to each well (except 
to blank and NSB wells) and incubated for 16-20 h, at 4ºC. After  five washes with wash buffer, 200 l of 
Ellman’s Reagent were added and incubated in the dark for 180 min (corresponding to the time required for the 
Bo wells to reach 0.2-0.8 units of absorbance), at room temperature. Absorbance was read at 405 nm, in a 
Spectramax Plus 334 spectrophotometer (Molecular Devices, Silicon Valley, CA, USA) and insulin levels were 
calculated by plotting B/Bo (%) (y axis) vs. the concentrations of insulin standards (x axis). Results were 
expressed as ng insulin/ml plasma. 
Insulin resistance degree was given by HOMA-IR calculation through the following formula:  
HOMA-IR = (20*fasting insulin)/(fasting glucose-3, 5) and results were expressed as arbitrary units.  
 
2.10. Blood cholesterol and triglycerides levels 
Blood cholesterol and triglycerides levels were determined after and before treatment, after caudal vein 
or intracardial blood collection, using the respective Accutrend kit with compatible stripes. Results were 
expressed as mg cholesterol or triglycerides/dl blood. 
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2.11. Blood pressure 
Blood pressure was measured using a LE 5001 Non Invasive Blood Pressure meter. The system used is 
based on the sphygmomanometric technique (the same used to take pressure in human beings). The unit 
features a pressure cuff, whose function is to occlude the passage of blood in the animal’s tail, and a transducer 
which captures blood pulses. Generally, both are placed on the animal’s tail to operate over the caudal artery. 
The LE 5001 detected the systolic or maximum pressure (SP) values, diastolic or minimum pressure (DP) 
values and the mean value, calculated as: MP=DP+0.33*(SP+DP). The heart rate was also picked up by the 
transducer. Its value was displayed continuously, and then stored along with the corresponding systolic, 
diastolic and mean pressure values. A measurement was comprised of the blood pulse (heart rate) and systolic 
and diastolic pressure values. Blood pressure was measured pre and post-treatment, before performing the 
glucose tolerance test. 
 
2.12. Preparation of brain cortical membranes, cytosolic homogenates and isolated 
mitochondria 
From the initial thirteen animals/group (Wistar placebo, GK placebo and GK plus Ex-4), brains from ten 
rats/group were immediately removed after animals’ sacrifice, weighed and dissected into cortex, hippocampus 
(the most affected areas in AD 
194
), hypothalamus and cerebellum. Cortices were immediately snap-frozen (-
80ºC) for subsequent analysis (except for freshly-isolated brain cortical mitochondria, as described later). Then, 
a portion of cortex per brain hemisphere was slowly thawed, rapidly washed, minced and homogenized in lysis 
buffer containing (in mM): 25 HEPES, 2 MgCl2, 1 EDTA, 1 EGTA (pH 7.5), supplemented with 100 M 
phenylmethanesulfonylfluoride (PMSF), 2 mM dithiothreitol (DTT), PhosSTOP Phosphatase Inhibitor Cocktail 
Tablets and Complete, Mini, EDTA-free Protease Inhibitor Cocktail Tablets (the last ones according to 
manufacturer’s instructions). Homogenization was done in a Potter-Elvejhem homogenizer with a Teflon pestle, 
at 300 rpm, 4ºC. Cortical homogenates were then centrifuged at 14 000 rpm for 10 min, 4ºC, in an Eppendorf 
5415C centrifuge, to remove non-lysed tissue. The supernatants were then removed and pellets were centrifuged 
again at 14 000 rpm, for 10 min, 4ºC, to separate membrane and total cytosolic fractions. The resultant pellets 
(membrane fractions) and supernatants (cytosolic fractions) were further collected and assayed for protein 
content by the Sedmak method, as described below. 
Regarding freshly-isolated brain mitochondrial fractions, we used a previously described procedure 
195
. 
Briefly, a portion of the cortex was depleted from myelin and homogenized in a Potter-Elvejhem homogenizer 
with a Teflon pestle, in 10 ml of isolation medium containing (in mM): 225 mannitol, 75 sucrose, 5 HEPES, 1 
EGTA (pH 7.4), supplemented with 1mg/ml fatty acid-free bovine serum albumin (BSA) and 750 l protease 
from Bacillus licheniformis, Type VIII (E.C. 232-752-2), at 200 rpm, 4ºC. Then, an equal volume of isolation 
medium plus BSA fatty acid-free was added to the homogenate and centrifuged at 2500 rpm, 5 min, at 4ºC, in a 
Sorvall Evolution RC Superspeed centrifuge (Thermo Scientific, Waltham, Massachusetts, USA). The resulting 
pellet was discarded and supernatant was further centrifuged at 10 000 rpm, for 10 min, at 4ºC. Then, the 
resulting supernatant was discarded and the pellet was resuspended in 10 ml of isolation medium supplemented 
with BSA fatty acid-free and 50 l of 20 mg/ml digitonin, and further centrifuged at 10 000 rpm, 10 min, at 
4ºC. The supernatant was removed and the remaining pellet was carefully resuspended in 10 ml of isolation 
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medium supplemented with BSA fatty acid-free, being subsequently centrifuged at 10 000 rpm, 5 min, at 4ºC. 
Finally, 10 ml resuspension medium (containing, in mM: 225 mannitol, 75 sucrose, 5 HEPES (pH 7.4)) were 
added to the resulting pellet and, after a new centrifugation at 10 000 rpm, 5 min, at 4ºC, the new pellet was 
resuspended in 100 l resuspension medium, collected, assayed for protein content by the Biuret method (as 
described below) and then kept at -80ºC for further analysis. 
 
2.13. Protein quantification 
To quantify protein there are several colorimetric or chromogenic methods available, whose utilization 
very commonly depend on protein composition as well as quantity. Regarding the protein composition, it can 
include amino acid content, any material bound covalently, such as carbohydrates, and protein conformation.  
The Biuret method is based on the complex interaction of cupric ions with proteins. In this reaction, 
copper sulphate is added to a protein solution in strong alkaline solution and the complex formed between the 
cupric ions and the peptide bonds, has a purplish-violet color 
196
. The reaction was named based on biuret and 
the similar colored complex it forms with cupric ions. To use this method, protein composition is not relevant 
because biuret reaction with proteins is independent on their composition. However, protein purity and 
association state could influence the results obtained with the biuret reagent 
197
.  
After a 15 min incubation, the reaction extent was colorimetrically measured at 540 nm in a Spectramax 
Plus 334 spectrophotometer (Molecular Devices, Silicon Valley, CA, USA), and protein levels were determined 
by comparison with the standard curve. Results were given as mg protein/ml sample. 
This technique was prepared accordingly: 
 
Table I. Experimental procedure for protein quantification using the Biuret method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
BSA 
(0.4%) (µl) 
 
Sample 
(µl) 
 
MilliQ H2O 
(µl) 
 
Ressuspension  
Buffer (µl) 
 
Doc 10% 
(µl) 
 
Biuret 
(ml) 
1 0  500 20 50 2 
2 250  250 20 50 2 
3 375  125 20 50 2 
4 500  0 20 50 2 
       
S1  20 500  50 2 
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The Sedmak method is another assay used to quantify proteins in solution and involves the use of low 
concentrations of perchloric acid (HClO4) or other acids, allowing the proteins to remain soluble. This 
technique, first described by Sedmak and Grossberg 
198
 was prepared accordingly:  
 
Table II. Experimental procedure for protein quantification using the Sedmak method 
  
MilliQ H2O 
(µl) 
 
BSA 0.1% 
(µl) 
 
Protein (µg) 
 
Lysis Buffer 
supplemented 
(µl) 
 
SEDMAK 
reagent (µl) 
P0 98 0 0 2 200 
P2 96 2 2 2 200 
P5 93 5 5 2 200 
P10 88 10 10 2 200 
P20 78 20 20 2 200 
    Sample (µl)  
S1 98   2 200 
S2 98   2 200 
 
Sedmak reagent: 0,06% of Coomassie brilliant Blue G250 in 3% HClO4  
After a 15 min incubation, the reaction extent was colorimetrically measured at 620 nm in a Spectramax Plus 
334 spectrophotometer (Molecular Devices, Silicon Valley, CA, USA) and protein levels were determined by 
comparison with the standard curve. Results were given as mg protein/ml sample. 
 
2.14. Brain cortical GLP-1, insulin and glucose levels 
          Brain cortical levels of GLP-1 were determined using a sandwich-ELISA-based kit, according to 
manufacturer’s instructions. Briefly, 20 l of brain cortical homogenates (prepared as above-mentioned) or 
standards were pipetted onto a provided micro ELISA plate pre-coated a specific antibody against GLP-1, 
mixed and incubated for 90 min at 37ºC. Then, the liquid was removed and 20 l of biotinylated detection 
antibody working solution was added to each well and incubated for 1 hour at 37ºC. After three washes with 
wash buffer solution, 20 l Avidin-Horseradish Peroxidase (HRP) conjugate working solution were added and 
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incubated for 30 minutes at 37ºC. After five new washes, 90 l substrate solution were added to each well and 
incubated for about 15 minutes at 37ºC, protected from light. During this step, wells containing GLP-1, 
biotinylated detection antibody and Avidin-HRP conjugate became blue colored. The enzyme-substrate reaction 
was stopped by addition of 50 l sulphuric acid solution (Stop solution) and wells turned yellow. Absorbance 
was then spectrophotometrically measured at 450 nm, in a Spectramax Plus 334 spectrophotometer (Molecular 
Devices, Silicon Valley, California, USA). GLP-1 levels in our samples were obtained by comparison with a 
standard curve containing known amounts of GLP-1. This kit’s sensitivity was 9.38 pg/ml, with a detection 
range from 15.63-1000 pg/ml, a coefficient of variation <10% and recognizing both natural and recombinant 
GLP-1, but without significant cross-reactivity or interference between rat GLP-1 and analogues. Results were 
expressed as pg GLP-1/mg protein.  
Brain cortical insulin levels, were determined using the above-mentioned Rat Insulin Enzyme 
Immunoassay Kit (please, see Section 2.9.). Results were expressed as ng insulin/mg protein. 
Glucose levels were also determined in brain cortical homogenates through the QuantiChrom Glucose 
Assay Kit, according to manufacturer's instructions. Briefly, 2.5 μl of each brain homogenate was diluted in 250 
μl reagent and heated in a heat block for 8 min. Then, the sample mix was cooled down in cold water bath for 4 
min and 200 μl of such sample mix were transferred into a 96-well plate. Absorbance was measured in a 
Spectramax Plus 334 spectrophotometer, at 630 nm. Calculations were made by plotting the obtained 
absorbance values (upon subtraction of blank absorbance) against known standard glucose concentrations. 
Results were expressed as mg glucose/mg protein.  
 
2.15. Western blotting analysis of brain cortical GLP-1R, Bcl2, Bax, cytochrome c, caspase-
12 cleavage, LC3II, P-mTOR, beclin-1, PI3K III, synaptophysin, PSD-95, RIP3 and 1  
Brain cortical total cytosolic homogenates or, whenever specified, brain cortical isolated mitochondria 
(50 l), all prepared as previously described, were denatured with SDS sample buffer (containing 0.7 M 4x 
Tris.Cl/SDS pH 6.8, 30% glycerol, 10% SDS, 0.6 M DTT and 0.012% bromophenol blue), at 100ºC, for 5 min 
and then subjected to SDS/polyacrilamide gel (8, 10 or 15%, composed 1.5 M Tris (pH 8.8), 40% acrylamide, 
10% (m/v) SDS, 10% ammonium persulfate (APS) and TEMED) electrophoresis (SDS-PAGE), at 130/140 V, 
in a buffer containing (in mM): 25 Tris-HCl (pH 8.0-8.5), 192 glycine and 0.1% (m/v) SDS (BioRad, Hercules, 
CA, USA). Then, samples were transferred onto polyvinylidene difluoride (PVDF) membranes (Immobilon®-P 
PVDF transfer membranes 0.45 μm), using a transfer buffer composed by 25 mM Tris-HCl (pH 8.0-8.5), 192 
mM glycine, 20% (v/v) methanol and 0.005% (m/v) SDS (BioRad), for 90 min,  at 0.75 A, 4ºC. The membranes 
were then blocked for 1 h at room temperature in 5% BSA (with 0.05% Tris-buffered saline (TBS)-Tween, 
which composition is 10% TBS 10x, 90% H2O miliQ and 0.05% Tween-20). Membranes containing subcellular 
proteins were incubated overnight, at 4ºC, with rabbit polyclonal anti-LC3 antibody (1:1000, in 0.05% TBS-
Tween plus 1% BSA), mouse monoclonal anti-beclin 1 (1:1000, in 0.05% TBS-Tween plus 1% BSA), rabbit 
polyclonal anti-P-mTOR antibodies (1:1000, in 0.05% TBS-Tween plus 5% BSA), rabbit monoclonal anti-PI3K 
III (1:1000, in 0,05% TBS-Tween plus 5% BSA), rabbit polyclonal anti-RIP1 (1:2000, in 0,05% TBS-Tween 
plus 1% BSA) and rabbit polyclonal anti-RIP3 (1:1000, in 0.05% TBS-Tween plus 1% BSA), rabbit polyclonal 
anti-BAX and anti-Bcl2 (1:1000, in 0.05% TBS-Tween plus 5% BSA), mouse monoclonal anti-cytochrome c 
(1:750, in 0.05% TBS-Tween plus 5% BSA), rabbit polyclonal anti-TOM20 (1:500, in 0,05% TBS-Tween plus 
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5% BSA), rabbit polyclonal anti-GLP-1R (1:1000, in 0.05% TBS-Tween plus 1% BSA), rabbit polyclonal anti-
caspase 12 (1:1000, in 0,05% TBS-Tween plus 1% BSA), rabbit monoclonal anti-PSD-95 (1:1000, in 0.05 
TBS-Tween plus 1% BSA), mouse monoclonal anti-synaptophysin (1:1000, in 0.05% TBS-Tween plus 1% 
BSA). Membranes were also labeled with mouse monoclonal anti-actin (1:5000, in 0.05% TBS-Tween plus 1% 
BSA) or rabbit monoclonal anti-α-tubulin (1:1000, in 0.05% TBS-Tween plus 5% BSA) antibodies, as loading 
controls. After the analysis of P-mTOR, membranes were further reprobed with mouse monoclonal anti-mTOR 
(1:1000, in 0.05% TBS-Tween plus 1% BSA). Then, membranes were washed three times with 0.05% TBS-
Tween, for 5 min, and incubated with anti-rabbit or anti-mouse IgG secondary antibodies (1:10000 or 1:20000, 
in 0.05% TBS-Tween plus 1% BSA), for 2 h at room temperature, with gentle shaking, and washed again with 
0.05% TBS-Tween for 5 min. Afterwards, membranes were developed using ECF fluorescence reagent. 
Immunoreactive bands were visualized by the Versa Doc Imaging System (BioRad, Hercules, CA, USA) and 
the fluorescence signal analysed using the QuantityOne software (BioRad, Hercules, CA, USA). Results were 
given as fluorescence intensity (INT)/mm
2
, being then normalized to the respective loading control.   
 
2.16. Co-immunoprecipitation of brain cortical IR and P-Tyr 
Analysis of active IR in brain cortical homogenates was followed after immunoprecipitation of IR using 
Protein A PLUS-Agarose Immunoprecipitation Reagent, according to manufacturer’s instructions with slight 
modifications. Briefly, cortical total cytosolic extracts (100 g) were mixed (gentle shaking) with 40 l of 
resuspended Protein A PLUS-Agarose and incubated for 30 min, at 4ºC. Then, beads were pelleted upon 
centrifugation at 2500 rpm in an Sorvall Evolution RC Superspeed centrifuge, for 5 min, at 4ºC, with 20 l of 
the resulting supernatant (Total control) being collected and kept on ice until futher analysis. The remaining 20 
l of supernatant were then incubated with 5 l rabbit monoclonal anti-IR (-subunit) primary antibody for 1 h, 
at 4ºC. An additional 20 l volume of resuspended Protein A PLUS-Agarose was then added to the previous 
mix and incubated for further 2 h, at 4ºC. After a centrifugation at 2500 rpm for 5 min, 4ºC, the pellet was 
collected and washed four times in 1 ml phosphate saline buffer (PBS), containing (in mM): 137 NaCl, 10 
Na2HPO4, 1.8 KH2PO4, 2.7 KCl (pH 7.3), with 20 l of the supernatant resulting from the second wash (Non-
immunoprecipitated control) being collected and kept on ice until futher analysis. After the final wash, the 
supernatant was discarded and the pellet resuspended in 40 l of 1x electrophoresis buffer (please, see Section 
2.15.), boiled for 2-3 min and centrifuged at 14 000 rpm, for 5 min, at 4ºC, using Spin-X
®
 centrifuge tubes with 
filter (0.45 m cellulose acetate in 2.0 ml polypropylene tube) to separate the Protein A PLUS-Agarose beads. 
Samples containing immunoprecipitated denatured IRs were immediately subjected to SDS-PAGE (10%) 
analysis, as described in Section 2.15. 
 
2.17. Analysis of membrane lipids and DNA oxidation 
The extent of lipid peroxidation was determined by measuring thiobarbituric acid reactive substances 
(TBARS), using the thiobarbituric acid (TBA) assay 
199
, with slight modifications. This colorimetric assay 
detects, at 530 nm, the formation of a pink complex resulting from the reaction, in acidic medium, between 
TBA and malondialdehyde (MDA), a product of lipid oxidation.  
Briefly, 10 l of brain cortical homogenates were boiled in 100 l of a peroxidation reagent containing 
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0.375% TBA, 15% tricholoacetic acid (TCA), 0,05% HCl 5M, for 10 min. Then, samples were cold on ice and 
centrifuged for 10 min at 3000 rpm, in an Eppendorf 5415C centrifuge. The resulting supernatant was collected 
onto a 96 well plate and the absorbance was measured at 530 nm in a Spectramax Plus 334 spectrophotometer, 
against a blank prepared in similar conditions, but in the absence of protein. The amount of TBARS formed was 
calculated using a molar extinction coefficient of 1.56x10
5
 M
-1
cm
-1
 and expressed as pmol TBARS/mg protein. 
The levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG, a well known DNA oxidation marker) were 
determined by using the 8-Hydroxy-2-deoxy Guanosine EIA kit according to manufacturer’s instructions. This 
immunoassay is based on the competition between 8-OHdG and a 8-OHdG-acetylcholinesterase (AChE) 
conjugate (8-OHdG Tracer) for a limited amount of 8-OHdG Monoclonal antibody. As the tracer amount 
remains constant and 8-OHdG varies, the amount of tracer able to bind to the monoclonal antibody is inversely 
proportional to the concentration of 8-OHdG in the sample. The complex antibody-8-OHdG binds to goat 
polyclonal anti-mouse IgG previously attached to the well. After washing to remove unbound reagents, 
Ellman’s reagent (containing the substrate for AChE) is added to the well, yielding a yellow product that 
strongly absorbs at 412 nm and whose color intensity, spectrophotometrically measured, is proportional to the 
amount of 8-OHdG Tracer bound to the well, which is in turn inversely proportional to the amount of free 8-
OHdG present in the well. Importantly, the 8-OHdG antibody used herein recognizes both free 8-OHdG and 
DNA-incorporated 8-OHdG. 
Briefly, 100 l and 50 l EIA buffer were added to NSB and B0 wells, respectively. Then, 50 l of brain 
cortical homogenates or 8-OHdG EIA standards were pipetted onto the respective wells, followed by the 
addition of 50 l 8-OHdG AChE Tracer (except to Total Activity (TA) and Blank (Bl) wells) and by 50 l 8-
OHdG EIA Monoclonal Antibody (except to TA, NSB and Bl wells). After 18 h of incubation at 4ºC, wells 
were washed for five times with wash buffer and incubated with 200 l Ellman’s reagent (plus 5 l tracer, only 
in TA wells), for 90 to 120 min (until B0 wells become 0.3-1.0 a.u., after Bl subtraction), with gentle shaking 
and protected from light. Absorbance was measured at 405 nm, on a Spectramax Plus 334 spectrophotometer. 
Sample concentrations of 8-OHdG were calculated after plotting the logit B/B0 for standards vs. log standard 
concentrations, followed by linear regression fit. Detection limit: 80% B/B0: ~30 pg/ml. Sensitivity: 50% 
B/B0: ~100 pg/ml. Results were expressed as pg 8-OHdG/mg protein.  
 
2.18. Colorimetric activation of caspases-like activities 
Conversion of procaspases into active caspases is generally accepted as one of the most reliable 
indicators of apoptosis, particularly in the case of the effector caspase-3 
200
. Caspases-3-, -8-, -1-, -2- and -9-like 
activities were determined by following a previously described procedure 
201
, with slight modifications. Briefly, 
twenty five (for caspases-3- and -8-like), forty (for caspases -1- and -2-like) or sixty-five (for caspase-9-like) g 
of brain cortical cytosolic homogenates were added to a reaction buffer containing 25 mM HEPES, 10% (m/v) 
sucrose, 0.1% (m/v) 3-[(3-cholamidopropyl) dimethylammonio]-1-propane-sulfonate (CHAPS) (pH 7.5), 
supplemented with 10 mM DTT and the respective colorimetric substrate (100 M) for caspases-3 (N-acetyl-
Asp-Glu-Val-Asp-P-nitroanilide, Ac-DEVD-pNA), -8 (N-acetyl-Ile-Glu-Thr-Asp-P-nitroanilide, Ac-IETD-
pNA), -1 (N-acetyl-Tyr-Val-Ala-Asp-P-nitroanilide, Ac-YVAD-pNA), -2 (N-acetyl-Val-Asp-Ala-Val-P-
nitroanilide, Ac-VDAV-pNA) and -9 (N-acetyl-Leu-Glu-His-Asp-P-nitroanilide, Ac-LEHD-pNA)-like 
activities. The reaction mixtures were incubated at 37ºC for 2 h, and the formation of pNA was measured at 405 
32 
 
nm in a Spectramax Plus 334 spectrophotometer. Caspases-like activities were expressed as percentage of 
control (caspase 1: 100% ± 19.95; caspase 2: 100% ± 37.54; caspase 8: 100% ± 22.64; caspase 9: 100% ± 
10.94; caspase 12: 100% ± 12.26; 100% ± 8.703). 
 
2.19. Data analysis and statistics 
Data were analyzed and results were presented as mean ± SEM of the indicated number of independent 
experiments, each corresponding to one animal. Statistical significance was analyzed using the paired Student t 
test for single comparisons or non-parametric one-way ANOVA for multiple comparisons, with the Bonferroni 
post-test. P < 0.05 was considered significant. 
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CHAPTER 3 
RESULTS 
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_____________________________________________ 
1 
The results presented throughout this chapter were obtained in coauthoring with Emanuel Candeias MSc.    
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3.1. Animals’ peripheral characterization 
In this study, we used middle-aged (8 month-old), male, non-diabetic male Wistar (controls) and T2D 
GK rats. As described in Materials and Methods section, animals were monitored before and after treatment. 
We observed that, before treatment, GK rats had significantly lower body weight than Wistar ones (421.1± 3.88 
vs. 461.9 ± 8.71 g in Wistar and GK rats, respectively) (Fig. 3.1.A). Although this difference was maintained 
after treatment, Ex-4 was not able to significantly restore body weight in GK rats to control values (Fig. 3.1.B). 
These results suggested that Ex-4 may not have an anorectic effect in our experimental conditions. 
Regarding the evaluation of peripheral T2D hallmarks, occasional blood glucose, blood glucose 
clearance response after a glucose load (given by the GTT) and HbA1C levels, pre-treated 8 month-old GK rats 
clearly showed a 3-fold higher glycemia (Fig. 3.1.C), a lower capacity to recover from a glucose load by 
clearing it from blood (given by their significantly higher blood glucose levels throughout the whole GTT test 
(Fig. 3.1.E) and their 3.4-fold higher area under the curve when compared to age-matched Wistar rats (Fig. 
3.1.G)). This was also accompanied by an approximately 1.8-fold higher HbA1C in GK rats before treatment 
(Fig. 3.1.I). Although by the end of treatment Ex-4-treated T2D rats had a 24% lower blood glucose levels than 
age-matched placebo GK rats, these differences did not reach statistical significance (Fig. 3.1.D). However, the 
recovery capacity of Ex-4-treated GK rats after the glucose load was highly improved after treatment, as given 
by the similarity in their blood glucose levels at the beginning and the end of the GTT test (Fig. 3.1.F) and by 
the 15% lower area under the curve in Ex-4-treated vs. placebo-treated GK rats (Fig. 3.1.H). Additionally, after 
a 28 days’ treatment, Ex-4 also significantly decreased HbA1c levels in T2D rats (from 8.29±0.19 to 7.34±0.28 
% in placebo-treated vs. Ex-4-treated GK rats, respectively) (Fig. 3.1.E). Thus, these results suggested that 
chronic peripheral administration of Ex-4 was able to counteract one of the main T2D peripheral hallmarks: the 
hyperglycemic, glucose-intolerant profile of middle-aged GK rats.  
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Figure 3.1. Animals’ peripheral characterization. Body weight (A, B), occasional blood glucose levels (C, D), blood 
glucose clearance capacity (E-H) and glycosylated hemoglobin (HbA1c) (I, J) were determined in non-diabetic Wistar and 
T2D GK rats before (A, C, E, G, I) and after treatment with Ex-4 (B, D, F, H, J). Middle-aged (8 month-old) Wistar and 
GK were subjected to the continuous subcutaneous delivery of 5 g/kg/day Ex-4 (or placebo), for 28 days. Occasional 
blood glucose levels were obtained by the glucose oxidase reaction (from caudal vein blood), using a commercial 
glucometer and compatible reactive tests. Blood glucose clearance capacity was given by the GTT test, consisting on the 
measurement of caudal vein blood glucose levels before and 15, 30, 60 and 120 min after an intraperitoneal bolus of 2 mg 
D-glucose/g body weight, as well as on the determination of the overall GTT area under the curve. Glycosylated 
hemoglobin (HbA1C) is an index of the average glycemias in the previous 2-3 months, being obtained from blood from 
caudal vein, using an appropriate kit and compatible reaction tests.  Data are expressed as mean ± SEM of 9 to 26 animals 
per group. Statistical significance: ***P<0.001 vs. Wistar control rats; 
#
P < 0.05, 
##
P<0.01 vs. placebo-treated GK rats. 
 
Given that one of the primary effects of Ex-4 is to stimulate insulin secretion 
181
, we also evaluated its 
effect on GK rats’ plasma insulin content and their insulin resistant profile (as given by the HOMA-IR profile) 
after treatment (Fig. 3.2.A and B). Regarding plasma insulin, we observed that its levels were approximately 
1.6-fold higher in the placebo-treated T2D rats than in age-matched controls (in accordance with Moreira et al. 
(2007) 
202
, who described that, at the initial stages of the disease, GK rats may have a certain degree of 
hyperinsulinemia) and that chronic Ex-4 treatment was not able to further increase plasma insulin content in GK 
rats (Fig. 3.2.A). However, from the evaluation of insulin resistance, we observed that chronic Ex-4 induced a 
32.9% decrement in HOMA-IR index in T2D rats compared to placebo-treated T2D rats (Fig. 3.2.B). 
Importantly, these results suggested that, as expected, our middle-aged GK rats were already insulin resistant 
(another feature of T2D) and peripheral Ex-4 therapy was able to ameliorate this parameter in GK rats. 
Overall, these results suggested that the chronic peripheral continuous delivery of Ex-4 significantly 
ameliorated the main peripheral features of T2D in middle-aged GK rats. 
 
 
 
 
 
 
 
 
 
Figure 3.2. Effect of chronic continuous peripheral Ex-4 treatment on plasma insulin levels and insulin resistance 
in T2D GK rats. After treatment and animals’ euthanasia, blood was collected by transcardial punction and plasma was 
obtained upon a 14 000 rpm centrifugation for 2 min, at 4ºC. Plasma insulin levels were determined by the Rat Insulin 
EIA Kit (according to manufacturer’s instructions) and the HOMA-IR index calculated by using the formula: HOMA-IR 
= (20*fasting insulin)/(fasting glucose-3.5). Data are expressed as mean ± SEM of 11 to 13 animals per group. Statistical 
significance: **P<0.01, ***P<0.001 vs. Wistar control rats; 
##
P<0.01 vs. placebo-treated GK rats. 
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As increased blood cholesterol and triglycerides are widely known to be increased upon T2D 
180
, we also 
evaluated the effect of Ex-4  on these parameters (Fig. 3.3. A-D). Although blood cholesterol levels were not 
significantly different between the experimental groups tested after treatment (Fig. 3.3. A), regarding blood 
triglycerides we observed that Ex-4 slightly (but not significantly) decreased triglyceride content in GK rat 
blood (Fig. 3.3.B). Regarding systolic blood pressure, as its values were highly variable between animals, we 
chose to establish different ranges of values and identify each range by an index, from 1 to 4. Thus, index 1 
corresponded to blood pressure values minor than 90 mmHg (low blood pressure), index 2 ranged from 90 to 
130 mmHg (normal blood pressure), index 3 ranged from higher than 130 to 300 mmHg (hypertension) and 
index 4 corresponded to blood pressure values higher than 300 mmHg (high blood pressure). We observed that 
systolic blood pressure degree was not different between the experimental groups in our procedure. Particularly, 
Ex-4 exerted no effect in blood pressure levels of the GK rats (Fig.3.3C). Overall, it seems only one animal of 
our population of GK rats was positively influenced by Ex-4 and had its values of blood pressure decreased. 
Therefore, these results suggest that, under our experimental conditions, Ex-4 may not significantly interfere 
with blood cholesterol and triglycerides’ metabolisms. In addition, we also did not observe a significant effect 
of Ex-4 in GK rats’ systolic blood pressures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Effect of subcutaneous Ex-4 administration on blood cholesterol, triglycerides and pressure in T2D 
rats. Immediately after animals’ euthanasia, blood was collected by transcardial punction and both cholesterol and 
triglycerides’ levels were determined using the respective Accutrend kit with compatible stripes, as described in Materials 
and Methods. Systolic blood pressure was measured from rats’ caudal artery, by a non-invasive sphyngomanometric 
technique composed by a tail pressure cuff and a transducer that captures blood pulses and sends the information towards 
a blood pressure meter. As systolic blood pressure values were highly variable between animals, we established scores 
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and identified each range of values in an index from 1 to 4. Thus, index 1 corresponded to blood pressure values lower 
than 90 mmHg (low blood pressure), index 2 ranged from 90 to 130 mmHg (normal blood pressure), index 3 ranged from 
higher than 130 to 300 mmHg (hypertension) and index 4 corresponded to values higher than 300 mmHg (high blood 
pressure). Data are expressed as mean ± SEM or median and respective quartiles (for systolic blood pressure scores) of 9 
to 13 animals per group. Statistical significance: *P<0.05 vs. Wistar control rats.  
 
3.2. Chronic peripheral Ex-4 administration did not affect T2D GK rat brain 
weight 
Immediately after the animals’ sacrifice, their brain was collected and weighed, in order to assess if 
peripheral administration of Ex-4 affected brain mass. Although previous studies reported that T2D leads to a 
pronounced brain atrophy and, therefore, to a lower brain weight 
2
, we did not observe significant differences 
neither between placebo-treated control and GK rats nor between Ex-4-treated and placebo-treated GK animals 
(Fig. 3.4.). These results suggest that middle-aged GK rats did not suffer from macroscopically-detectable brain 
atrophy and, therefore, Ex-4 did not exert any significant effect herein. 
 
  
 
 
 
 
 
 
Figure 3.4. Effect of peripheral Ex-4 treatment on rat brain weight. Immediately after rats’ euthanasia, brains were 
separated from the skull and weighed. Data are expressed as mean ± SEM of 8 to 10 rats per group.  
3.3. Effect of chronic peripheral treatment with Ex-4 on GK rat brain cortical 
GLP-1 levels and GLP-1R protein expression  
As Ex-4 is an agonist of GLP-1R, highly lipophylic and thereby able to readily cross the BBB and reach 
the brain intact, and GLP-1R is highly expressed in brain and activated by the drug 
183
, we measured both the 
levels of GLP-1 (Fig. 3.5.A) and the GLP-1R protein expression in brain cortical homogenates (Fig. 3.5.B). 
Although neither the 3.1-fold lower GLP-1 levels in placebo-treated nor their 2.4-fold increase in Ex-4-treated 
GK rat brain cortical homogenates reached statistical significance, these observations suggested that chronic 
subcutaneous delivery of Ex-4 for 28 days was sufficient to stimulate the synthesis of GLP-1 (either locally in 
brain and/or peripherally) (Fig. 3.5.A). However, these tendencies were not mirrored by the GLP-1R protein 
expression under the same conditions, as no significant differences were reported herein (Fig. 3.5.B). 
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Figure 3.5. Effect of chronic subcutaneous Ex-4 administration on GK rat brain cortical levels of GLP-1 and GLP-
1R protein expression. After animals’ sacrifice, brain cortical homogenates were prepared as described in Materials and 
Methods and GLP-1 levels were measured by a sandwich-ELISA-based kit, according to manufacturer’s instructions. 
GLP-1R protein expression was detected by SDS/PAGE (10%) electrophoresis followed by transfer into PVDF 
membranes and incubation with rabbit polyclonal anti-GLP-1R antibody. Then, membranes were reprobed with mouse 
monoclonal anti--actin. Data are expressed as mean ± SEM of six animals per group. 
 
3.4. The role of chronic subcutaneous Ex-4 treatment on GK rat brain cortical 
insulin levels and IR protein expression  
 Given the widely described effect of T2D on insulin levels, that brain insulin resistance is a common 
molecular link between T2D and AD, and that Ex-4 is known by its peripheral insulinotropic effect 
203
, we also 
analyzed the effect of chronic peripheral Ex-4 administration on insulin content and its receptor activation in 
brain cortical homogenates from GK rats. Surprisingly, we observed that Ex-4 was not able to recover from the 
44% decrease in GK rat brain cortical insulin levels (Fig. 3.6.A) and this was not accompanied by significant 
changes in IR activation (as given by its phosphorylation at tyrosine residues) (Fig. 3.6.B). These results suggest 
that the subsequent brain Ex-4 effects may not be mediated by a local increase in insulin levels nor by IR 
activation (at least in cortical region). 
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Figure 3.6. Effect of chronic subcutaneous Ex-4 therapy on T2D rat brain cortical levels of insulin and IR 
activation. After animals’ sacrifice, brain cortical homogenates were prepared as described in Materials and Methods and 
insulin levels were measured by the Rat Insulin EIA Kit (according to manufacturer’s instructions). IR activation was 
determined after co-immunoprecipitation of brain cortical homogenates with rabbit monoclonal anti-IR (-subunit) 
antibody, followed by SDS/PAGE (10%) electrophoresis, transfer into PVDF membranes and ultimately incubation with 
mouse monoclonal anti-phospho-tyrosine antibody. Data are expressed as mean ± SEM of six or two animals per group, 
regarding insulin levels and IR activation, respectively. Statistical significance: **P<0.01 vs. Wistar control rats. 
 
3.5. Effect of chronic subcutaneous Ex-4 administration on GK rat brain 
cortical glucose levels 
 As hyperglycemia has been widely described to be one of the crucial players in T2D-related brain 
damage and chronic complications (including dementia and AD) 
12,204
 and given the anti-T2D effect of Ex-4 , 
we measured the brain cortical levels of glucose(Figure 3.7). Although placebo-treated GK rats had a 1.4-fold 
higher brain cortical glucose levels than age-matched placebo-treated Wistar rats, revealing that their brain 
glucose content was mirroring their peripheral hyperglycemia (Fig. 3.7.), and Ex-4 was able to restore GK rat 
brain glucose levels to values nearly those from control rats (0.012±0.001 mg glucose/mg protein), these 
differences did not reach statistical significance (Fig. 3.7.). Nevertheless, these results suggested that Ex-4 
might be exerting an anti-hyperglycemic effect also in T2D CNS. 
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Figure 3.7. Effect of chronic subcutaneous Ex-4 administration on T2D rat brain cortical glucose levels. After 
animals’ sacrifice, brain cortical homogenates were prepared as described in Materials and Methods and glucose levels 
were determined by the QuantiChrom Glucose Assay Kit, according to manufacturer's instructions. Data are expressed as 
mean ± SEM of six animals per group. 
 
3.6. The role of chronic subcutaneous Ex-4 treatment on oxidative stress 
markers in GK rat brain cortex  
 Oxidative stress, resulting from an imbalance between the increased formation of ROS and/or impaired 
antioxidant defense mechanisms, has been widely described to play a deleterious role both in T2D and AD 
brain, leading to lipid, protein and DNA oxidation and subsequent cellular damage 
11
. This is of the outmost 
importance, as brain is highly susceptible to oxidative injury 
205
. As oxidative stress is a highly dynamic 
process, the successful detection of ROS levels/formation in tissues is often very difficult. Thus, we indirectly 
assessed oxidative stress in our experimental conditions by measuring the levels of other secondary byproducts, 
namely the TBARS and 8-OHdG, to evaluate both lipid and DNA oxidation, respectively (Fig. 3.8.A and B).  
 We observed that although TBARS levels were only 13.8% higher in placebo-treated T2D GK rat brain 
compared to placebo-treated Wistar rats, and Ex-4 lowered these values by 23%, these differences did not reach 
enough statistical significance (Fig. 3.8.A). Conversely, both placebo- and Ex-4-treated GK rats presented 
17.5% and 18.9% lower 8-OHdG levels than placebo-treated Wistar and GK rats, respectively (Fig. 3.8.B). 
However, none of these differences reached statistical significance. These results suggested that Ex-4 was trying 
to counteract the T2D-related lipid and DNA oxidative injury in rat brain cortex. 
 
 
 
 
 
 
 
Figure 3.8. Effect of chronic subcutaneous Ex-4 administration on T2D rat brain cortical lipid and DNA oxidation. 
After animals’ sacrifice, brain cortical homogenates were prepared as described in Materials and Methods. Lipid 
oxidation was given by the colorimetric detection, at 530 nm, of TBARS levels upon the formation of a pink complex 
resulting from the reaction, in acidic medium, between thiobarbituric acid and the lipid oxidation product 
malondialdehyde. DNA oxidation was given by the measurement of 8-OHdG by the 8-Hydroxy-2-deoxy Guanosine EIA 
kit according to manufacturer’s instructions. Data are expressed as mean ± SEM of six animals per group. 
 
3.7. Effect of chronic peripheral administration of Ex-4 on autophagic 
mechanism in GK rat brain cortex  
Under physiological conditions, autophagy is a catabolic mechanism used for degradation of old and 
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damaged proteins and, therefore, contributing for cell survival; however, this process has been also recently 
implicated as a pivotal contributor for cell death upon severe damaging conditions 
29
. As autophagy has been 
implicated in T2D or even AD pathologies, but the evidences remain controversial, we next evaluated if Ex-4 
could have a (protective) effect on brain cortical autophagic mechanisms upon T2D.  
 First, we assessed protein expression levels of LC3-II in rat brain cortical homogenates (Fig. 3.9.A), one 
of the most commonly used markers of autophagy and a protein expressed in autophagosomes 
48
. Although 
LC3-II protein expression was decreased in placebo-treated GK rat brains compared to age-matched placebo-
treated Wistar rats (from 1.14±0.23 in control rats to 0.75±0.11 in T2D rats), and Ex-4 induced a 1.3- fold 
increase in LC3-II protein expression compared to placebo-treated GK rats (Fig. 3.9.A), these differences were 
not statistically significant. Then, we analyzed the protein expression levels of phospho-mTOR (P-mTOR), a 
key regulator of autophagy (Fig. 3.9.B). We observed that the placebo-treated T2D rat brains had 15.4% higher 
(although non-significant) P-mTOR/total mTOR than the placebo-treated controls, whereas Ex-4 returned its 
values to nearly control ones (Fig. 3.9.B). Another controller of the autophagic process is beclin-1 
49
. However, 
it is still unclear whether beclin-1 acts a negative or a positive regulator. Nevertheless, we determined its protein 
expression levels in rat brain cortical homogenates (Fig. 3.9.C). We observed that placebo-treated GK rats had a 
25.6% lower beclin-1 expression than the placebo-treated Wistar rats, whereas in Ex-4-exposed GK rats its 
protein expression was only 9.3% higher than in non-treated GK rat brain (Fig. 3.9.C). However, none of these 
differences were statistically significant. Finally, another regulatory complex intrinsically involved in 
autophagy is the PI3K class III 
49
, whose protein expression was also evaluated in our experimental conditions 
(Fig. 3.9.D). Similarly to beclin-1, PI3K class III protein expression was lower in placebo-administered GK rat 
brains than in Wistar rats (from 1.08±0.29 to 1.63±0.29, in GK placebo vs. Wistar placebo, respectively), and 
Ex-4 treatment induced a slight increase in PI3K class III protein expression in GK rats (to 1.37±0.31) (Fig. 
3.9.D). Although our results did not reach statistical significance, the tendencies observed suggested that the 
autophagic process could be slightly more activated in brain cortices from the Ex-4-treated GK rats, probably 
constituting a protective strategy against T2D-related brain degeneration and death. 
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Figure 3.9. Effect of chronic subcutaneous Ex-4 administration on T2D rat brain cortical autophagic markers. 
After animals’ sacrifice, brain cortical homogenates were prepared as described in Materials and Methods. LC3-II (A), P-
Mtor (B), beclin-1 (C) and PI3K class III (D) protein expression were detected by SDS/PAGE (10% or 15%) 
electrophoresis followed by transfer into PVDF membranes and incubation with rabbit polyclonal anti-LC3, rabbit 
polyclonal anti-P-mTOR, mouse monoclonal anti-beclin 1 and PI3K class III antibodies. Then, membranes were reprobed 
with rabbit monoclonal anti-α-tubulin, mouse monoclonal anti-mTOR and mouse monoclonal anti--actin antibodies. 
Data are expressed as mean ± SEM of six animals per group. 
 
3.8. Effect of peripheral exposure to Ex-4 on apoptotic cell death in GK rat 
brain cortex  
 
 Given our previous results on the possible Ex-4-induced slight activation of autophagy markers as an 
anti-cell death mechanism in T2D rat brain and some evidences on the anti-apoptotic role of Ex-4 
186,206–208
, we 
next assessed its effect on caspase-mediated apoptotic activation (Fig. 3.10). From the analysis of the caspases-
1- and -2-like activation (initiator caspases) 
74
, we observed that, despite the slight increase (32.9% for caspase-
2-like activation) and the decrease (26.3% for caspases-1-like activation) in placebo-treated GK rats compared 
to placebo-treated Wistar rats, Ex-4 induced a 11.2% and 17.1% decrement in the activation of both caspases in 
GK rat brain, respectively (Fig. 3.10.A,B). However, none of these differences reached statistical significance. 
Regarding caspase-8-like, initiator caspase mostly involved in the extrinsic pathway of apoptotic cell death 
209
, 
we observed that T2D induced a significant increase in its activation (to 139.6±26.8% of control Wistar rats) 
(Fig. 3.10.C). However, Ex-4 administration was not able to counteract this effect in GK rat brain (Fig. 3.10.C). 
Another putative pathway to induce apoptotic cell death involves the endoplasmic reticulum-related caspase-12, 
whose role in AD has been increasingly described 
91
. From the evaluation of caspase-12 cleavage, we did not 
observe significant changes between our experimental groups (Fig. 3.10.D). 
Besides the above-described initiator caspases, we also determined the activation of caspase-9-like, as 
this caspase is able to induce the downstream activation of the effector caspase-3 and, together with cytochrome 
c and the apoptotic protease-activating factor-1 (Apaf-1), caspase-9 forms the apoptosome complex 
67
. 
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Surprisingly, we did not observe significant changes between the different experimental conditions studied (Fig. 
3.10.E). 
Since the above results suggest that 1) T2D may exert some pro-apoptotic effect in rat brain cortex, 
mostly via the activation of the caspase-8-like extrinsic pathway, but also in a minor degree through the slight 
activation of caspase-2-like, and 2) Ex-4 slightly inhibited both caspases-1- and -2-like, we next evaluated the 
cleavage of the main effector caspase substrate – the caspase-3-like activation 60. Interestingly, we observed 
that, despite not statistically significant, GK rat brains had a 1.8-fold increment in caspase-3-like activation than 
age-matched Wistar rats (Fig. 3.10.F). Chronic peripheral administration of Ex-4 was able to reduce caspase-3-
like substrate cleavage by 37.2% in GK rats vs. placebo-treated GK rats (Fig. 3.10.F). Therefore, these results 
suggest that Ex-4 may exert its anti-apoptotic effect in T2D rat brain by blunting some intermediary molecule(s) 
from the apoptotic cascade and it is possible that the increase in autophagy may play a role herein, as discussed 
later. Amongst such possibly affected intermediary molecules, we analyzed the Bcl2 protein expression and 
translocation into the cytosol (in basal conditions, the main anti-apoptotic protein Blc2 remains attached to 
mitochondria, being translocated to the cytosol in the presence of apoptotic signals 
79
. Therefore, we measured 
Bcl2 protein expression in both mitochondrial and cytosolic fractions from brain cortical homogenates. As 
depicted in the typical immunoblotting image (Fig. 3.10.G), Bcl2 protein was only detected in mitochondrial 
fractions of all experimental conditions, suggesting that the eventual deleterious conditions associated to T2D 
were not sufficient to induce its translocation into the brain cortical cytosol in placebo-treated GK rats. 
Nevertheless, these rats showed a 1.5- fold decrement in mitochondrial expression of Bcl2 compared to 
placebo-treated Wistar rats (Fig.3.10.G). Conversely, Ex-4 treatment significantly restored Bcl2 protein 
expression in GK rat brain cortices to values similar to Wistar placebo rats (Fig. 3.10.G). One of the main pro-
apoptotic proteins is Bax, that usually relies in the cytosol, being translocated to the mitochondria during the 
apoptosis process 
79
. Although we did not detect any Bax protein expression in mitochondrial fractions from 
brain cortical homogenates under our experimental conditions (data not shown), its cytosolic expression was 
similar between Wistar and GK placebo rats (Fig. 3.10.H). Despite no significant changes, Ex-4-exposed GK 
rats had a 26.4% increment in cytosolic Bax protein expression compared to the GK placebo group. Finally, as 
cytochrome c translocation from mitochondria (whereby it relies under physiological conditions) to cytosol can 
be used as an additional apoptosis marker 
80
, we also evaluated its protein expression levels in both 
mitochondrial and cytosolic fractions of brain cortical homogenates (Fig. 3.10.I,J). Despite no significant 
changes between the experimental conditions, neither regarding cytosolic cytochrome c expression (Fig. 3.10.I) 
nor in mitochondrial expression (Fig. 3.10.J), there was a slightly increased expression of cytochrome c in the 
cytosol from GK placebo rats (by 9.1% compared to Wistar rats) that was decreased by 15.2 % upon Ex-4 
treatment (Fig. 3.10.I). 
 
 Overall, these results suggest that the Ex-4-mediated protection against caspase-3-induced apoptosis in 
T2D GK rat brain cortices may be due (at least partially) to the tendency to retain the anti-apoptotic Bcl2 and 
the proapoptotic cytochrome c within mitochondria, whereas the proapoptotic Bax remained in the cytosol 
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Figure 3.10. Effect of chronic peripheral administration of Ex-4 on T2D rat brain cortical apoptotic markers. After 
animals’ sacrifice, brain cortical homogenates were prepared as described in Materials and Methods. Caspases-1- (A), -2- 
(B), -8- (C), -9- (E) and -3-like activities were measured colorimetrically, at 405 nm, upon the cleavage of their specific 
substrates (Ac-YVAD-pNA, Ac-VDAV-pNA, Ac-IETD-pNA, Ac-LEHD-pNA and Ac-DEVD-pNA, respectively). 
Cleaved and full-length caspase-12 (D) were detected by SDS/PAGE (10%) electrophoresis followed by transfer into 
PVDF membranes and incubation with rabbit polyclonal anti-caspase 12 antibody. Bcl2 (G), Bax (H) and cytochrome c 
(I,J) translocation was evaluated by SDS/PAGE (10%) electrophoresis of both brain cortical cytosolic homogenates and 
isolated mitochondrial fractions, followed by transfer into PVDF membranes and incubation with rabbit polyclonal anti-
Bcl2 or anti-Bax antibodies. Then, membranes were reprobed with mouse monoclonal anti--actin or TOM20. Data from 
caspases-like activation are expressed as percentage of control and represent the mean ± SEM of six to 10 animals per 
group. Statistical significance: *P<0.05 vs. placebo-treated Wistar rats; 
##
P<0.01 vs. placebo-treated GK rats.  
 
3.9. The role of peripheral administration of Ex-4 on necrotic cell death in GK 
rat brain cortex  
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 Herewith, we assessed the effect of T2D on rat brain cortical necrotic death and the role for chronic 
peripheral administration of Ex-4, through the analysis of RIP1 and RIP3, two key regulator proteins of necrosis 
104
, protein expression levels (Fig. 3.11.A and B). Although there were no significant differences between our 
experimental groups regarding both RIP1 (Fig. 3.11.A) and RIP3 (Fig. 3.11.B) protein expression levels, a 
slight, 12% increase in the expression of RIP1 protein occurred in Ex-4-treated GK rat brain cortex (Fig. 
3.11.A). These results suggest that necrotic cell death may not underlie T2D-associated brain cortical damage. 
 
  
   
 
 
 
 
 
   
  
 
Figure 3.11. Effect of chronic peripheral administration of Ex-4 on T2D rat brain cortical necrotic markers. After 
animals’ sacrifice, brain cortical homogenates were prepared as described in Materials and Methods. RIP1 (A) and RIP3 
(B) protein expression was evaluated by SDS/PAGE (10%) electrophoresis of brain cortical homogenates, followed by 
transfer into PVDF membranes and incubation with rabbit polyclonal anti-RIP1 and rabbit polyclonal anti-RIP3 
antibodies. Then, membranes were reprobed with mouse monoclonal anti--actin. Data are expressed as mean ± SEM of 
six animals per group. 
 
3.10. Effect of peripheral administration of Ex-4 on synaptic function in GK 
rat brain cortex  
 As T2D has been described to negatively affect brain synaptic function 
124,210
, finally we assessed the 
effect of Ex-4 on brain synapses through the analysis of protein expression of both the post-synaptic domain-95 
(PSD-95, a synapse-associated protein located in the post-synaptic membrane 
211
(Fig. 3.12.A) and the 
synaptophysin proteins (a major protein of synaptic vesicles 
212
(Fig. 3.12.B). As depicted in Fig. 3.12.A, 
although non-statistically significant, the placebo-treated GK rats had 1.3-fold higher PSD-95 protein 
expression than age-matched placebo-treated Wistar rats, that was further increased by Ex-4 treatment (to 
0.13±0.004). Regarding synaptophysin expression (Fig. 3.12.B), we observed that Ex-4  was able to restore its 
protein expression in T2D rat brains (from 1.74±0.39 in placebo Wistar rat brain to 1.23±0.35 in placebo GK 
rats and to 1.9±0.48 in Ex-4-treated GK rats). However, none of these differences reached statistical 
significance. These results suggested that Ex-4 was trying to restore brain cortical synaptic function in T2D GK 
rats. 
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Figure 3.12. Effect of chronic peripheral administration of Ex-4 on T2D rat brain cortical synaptic function. After 
animals’ sacrifice, brain cortical homogenates were prepared as described in Materials and Methods. PSD-95 (A) and 
synaptophysin (B) protein expression was evaluated by SDS/PAGE (10%) electrophoresis of brain cortical homogenates, 
followed by transfer into PVDF membranes and incubation with rabbit monoclonal anti-PSD-95 and mouse monoclonal 
anti-synaptophysin antibodies. Then, membranes were reprobed with mouse monoclonal anti--actin or rabbit monoclonal 
anti-α-tubulin. Data are expressed as mean ± SEM of six animals per group. 
 
Overall, our results suggest that Ex-4 is an effective anti-T2D drug able to simultaneously lower GK 
rats’ glycemia and HbA1c, as well as insulin resistance (the main hallmarks of T2D). We also showed that 
chronic peripheral administration of Ex-4 was able to increase brain cortical GLP-1 levels upon T2D (although 
this insulinotropic drug was unable to increase plasma and cortical insulin levels). Additionally, despite no 
effect in brain necrotic cell death, Ex-4 effectively inhibited caspase-3-mediated apoptosis and activated 
autophagic mechanisms. Additionally, Ex-4 increased synaptic function and decreased brain cortical oxidative 
stress upon T2D. Although the differences between experimental groups of animals sometimes did not reach 
statistical significance, the tendencies observed herein appear to be promising and therefore deserve further 
clarification, e.g., by improving the number of samples analyzed.  
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Discussion 
T2D is a growing health care issue and a modern epidemic, thus rendering the discovery and/or the 
implementation of therapeutic strategies for its prevention and/or management of the outmost socioeconomic 
relevance. Given that hyperglycemia is a hallmark of T2D 
137
, a good glycemic control appears to be crucial to 
reduce the risk for the development of diabetic complications (particularly those affecting the CNS, as dementia 
and AD). As such, the development of new glucose-lowering agents for the treatment of T2D has been an 
imperative issue in the recent years. In this regard, as GLP-1 is the physiological responsible for most of the 
incretin effect 
184
 in non-diabetic individuals, but its action is highly limited by its vulnerability to degradation 
by DPP-IV (whose activity is coincidentally increased in T2D), a huge effort has been recently made to develop 
incretin mimetics (more resistant do DPP-IV degradation) or incretin receptor enhancers (that overcome the 
deficit in incretin system) to treat T2D. Amongst these drugs, we can consider both GLP-1 mimetics/GLP-1R 
agonists (as Ex-4) and DPP-IV inhibitors 
146
. Ex-4 is one of the most widely clinically used and best studied 
incretin-based anti-T2D therapy, that acts as an agonist of the GLP-1R 
180
. This peptide is obtained from 
lizard’s saliva and is resistant to DPP-IV 176. Importantly, due to its high lipophylicity, peripherally-
administered Ex-4 rapidly diffuses through the BBB into the CNS 
183
, whereby it has been increasingly shown 
to exert some neuroprotective effects 
213
 and, inclusively, led to the development of clinical trials aiming at its 
use against AD (ClinicalTrials.gov Identifier: NCT01255163). With all this in mind, we hypothesized herein 
that Ex-4 restores the T2D-associated alterations in intracellular quality control mechanisms, neurodegeneration 
and death, thereby improving synaptic function and, ultimately, cognitive function. Therefore, we aimed to 
study the effect of chronic, continuous peripheral administration of Ex-4 in T2D-related pathological features 
and other associated risk factors, as well as in middle-aged rat brain cortical oxidative stress and synaptic 
(dys)function markers, cellular quality control (autophagic) mechanisms and, finally, in neurodegeneration and 
cell death mechanisms. 
Regarding the impact of chronic peripheral treatment with Ex-4 on T2D pathology hallmarks, our 
observation that Ex-4 did not rescue the decrement in body weight in middle-aged GK rats suggested that, 
contrary to other “traditional” anti-T2D drugs 139, Ex-4 did not induce weight gain, neither had it the anorectic 
effect described by others. The observation that T2D GK rats had lower body weight than the age-matched 
Wistar controls was in line with our previous reports on an already decreased food intake and body weight 
210,214
, as well as with the description of GK rats as a non-obese T2D model 
215
. Regarding Ex-4, Young et al. 
(1999)
216
 reported that a chronic 5-6 week exposure to Ex-4 (either one-single dose and/or multiple dose 
treatment) decreased both food intake and body weight in the obese Zucker diabetic fatty (ZDF) rats 
(hyperglycemic,  insulin-resistant, obese, dyslipidemic rat models that succumb to β-cell failure at 12 to 14 
weeks of age) 
181
. Similar results were described in both obese and lean Zucker rats, as well as in normal 
rodents consuming a high fat diet, when submitted to a chronic intracerebroventricular Ex-4 treatment 
217,218
. 
Moreover, Ex-4 also successfully decreased body weight in a randomized clinical trial comparing once weekly 
vs. twice daily treatment 
219
.  
Importantly, our observations that Ex-4 treatment lowered occasional glycemia, HbA1C and HOMA-IR, 
and restored the rate of blood glucose clearance in middle-aged T2D rats, strongly suggested that Ex-4 was able 
to counteract the main T2D peripheral hallmarks in these animals: the hyperglycemic/glucose-intolerant and the 
insulin resistant profiles. These results were in accordance with our previous reports on the increased glycemia 
54 
 
and HbA1C (despite the lower food intake) in the 6 to 7 month-old GK rat model 
124,214
. Additionally, our results 
match those describing an Ex-4-mediated decrement in blood glucose levels and HbA1c 
175
. Indeed, Tourrel et al. 
(2002) 
220
 observed that 2 month old T2D GK female rats that were given Ex-4 during their pre-diabetic period 
(post-natal days 2-6) had a notably decreased plasma glucose level than their untreated counterparts 
220
. 
Moreover, Young e al. (1999) 
216
 described that an in vivo intraperitoneal administration of a single dose of Ex-
4 to hyperglycemic db/db mice (a model of T2D) potently reduced reducing plasma glucose, whereas chronic 
intraperitoneal administration of this drug (for 5 weeks, twice daily or for 6 weeks, once or twice daily) to male 
ZDF rats resulted in a significant decline in HbA1C. Similar effects of Ex-4 were provided by Szayna et al. 
(2000)
221
 in HbA1C levels from Zucker fatty rats submitted to a 42 day treatment. Interestingly, in a 30 week-
randomized clinical trial, Drucker et al. (2008) 
219
 reported that in patients treated with exenatide once a week 
changes in HbA1C were considerably higher than in those given exenatide twice a day. Interestingly, given that 
GK rats have been previously described to be mildly hyperinsulinemic and insulin resistant 
202
, it is not 
surprising that we observed an increase in plasma insulin levels in untreated rats. Moreover, as Ex-4 is an 
insulinotropic drug, ie, one of its primary effects is to stimulate insulin secretion 
203
, it is plausible that, despite 
no significant improvements in plasma insulin levels after treatment (probably due to the already increased 
insulin in this strain even before drug exposure), an Ex-4-mediated increase in insulin sensitivity might have 
occurred, as reported in other rodent models of T2D 
216,222
. 
Regarding the impact of Ex-4 on blood cholesterol and triglycerides levels, some controversy exists, as 
some authors described the drug was able to reduce only the cholesterol levels 
181
, whereas in others it 
diminished both cholesterol and triglycerides 
219
. In the present study, we observed that Ex-4 did not change 
blood cholesterol levels and, although not significantly, decreased blood triglyceride levels in GK rats. 
Similarly, the reports on the effect of Ex-4 in blood pressure are also controversial, ranging from an increased 
blood pressure after a chronic treatment 
223
 to a reduction after a once weekly administration 
161
.  
Although no significant changes between cohorts were observed in terms of brain weight, thereby 
suggesting that middle-aged GK rats did not suffer from macroscopically-detectable brain atrophy and that Ex-4 
treatment had no effect herein, previous studies reported that T2D leads to a pronounced brain atrophy and, 
therefore, to a lower brain weight 
2
.  
As previously described, Ex-4 is a GLP-1R agonist able to cross the BBB and reach the brain intact and, 
also relevant herein, its receptors are highly expressed in brain 
224,225
. In line with this, we first hypothesized 
that either the peripheral Ex-4 administration in T2D rats would 1) decrease the secretion of the endogenous 
GLP-1 due to a negative feedback mechanism, thus decreasing its brain cortical levels, or 2) it would further 
stimulate GLP-1 secretion and increase its levels in brain. As from the Fig. 3.5.A, we can infer that the chronic 
subcutaneous delivery of Ex-4 for 28 days was sufficient to overcome the tendentially lower brain cortical GLP-
1 levels in T2D rats, thus suggesting that this anti-T2D drug may stimulate the synthesis of endogenous GLP-1 
(either peripherally and/or centrally). Surprisingly, as this was not accompanied by significant changes in GLP-
1R protein expression levels between cohorts, it is plausible that, without treatment, T2D rat brain might be 
suffering from depletion in GLP-1 levels rather than an inhibition of its receptors. However, this needs to be 
further clarified, e.g., by analyzing if GLP-1R activities are significantly different between groups.   
Given the above-mentioned insulinotropic effect of Ex-4 and the increasingly suggested role for insulin 
resistance as a possible common molecular link between T2D and AD 
15,112
, we determined brain cortical 
insulin levels. To our surprise, despite the previously mentioned increase in plasma insulin content in T2D 
55 
 
compared to the age-matched non-T2D rats, its brain levels were significantly lower in the GK rat cohort and, 
similarly to the periphery, Ex-4 was not able to rescue brain cortical insulin content in GK rats. This suggested 
that, despite its well known insulinotropic effect (that was not observed peripherally under our experimental 
conditions); Ex-4 also did not stimulate insulin transport from the periphery into the GK rat brain nor its local 
brain synthesis. As with plasma, an alternative hypothesis was that Ex-4 could be increasing brain cortical 
insulin sensitivity instead. However, as no significant changes were observed in the activation profile of brain 
cortical IR (as given by the phospho-tyrosine/IR), it seems unlikely that Ex-4 was improving insulin sensitivity 
in GK rat brain. Rather, our results appear to point towards an insulin/IR-independent effect of Ex-4 in T2D rat 
brain (at least in cortical region). In line with this, we also observed that Ex-4 was able to restore GK rat brain 
cortical glucose levels to nearly those of age-matched Wistar placebo ones, thus protecting against the described 
damaging effects of T2D-associated high glucose levels in brain 
226
. To further support this hypothesis, we then 
analyzed the effect of this drug on brain oxidative markers. Oxidative stress is a highly dynamic process that 
arises from an imbalance between the increased formation of ROS and/or the decrement in antioxidant defenses, 
being the brain one of the most exposed and vulnerable tissues to the highly deleterious oxidative damage 
205
. 
Such CNS vulnerability is due to its high content on the easily-oxidizable polyunsaturated fatty acids, in 
transition metals (as iron and copper) and ascorbate, its high metabolic rate and to its lower content in 
antioxidant defenses 
205
. Interestingly, although no statistical differences were observed between the 
experimental groups, the Ex-4-treated diabetic rats had lower cortical levels of both lipid and DNA oxidation 
markers (TBARS and 8-OHdG, respectively). These results are in agreement with our previous studies, 
whereby no significant differences in lipid oxidation were reported between middle-aged Wistar and GK rat 
brains under basal conditions, whilst under an additional detrimental condition (e.g. the induction of an 
exogenous oxidative injury) the T2D rat brains were either less vulnerable (at 6 month old) 
210,214
 or unaffected 
(at 7 months of age) 
124
. Importantly, such decreased brain vulnerability of GK rat brains appeared to be 
independent from synaptosomal fatty acid composition or the antioxidant enzymes superoxide dismutase, 
glutathione oxidase and glutathione reductase; rather, it could be due to a higher content on the endogenous 
scavengers oxidized glutathione and vitamin E 
214
. Our present results on the Ex-4-mediated partial decrease in 
brain lipid and DNA oxidation was in accordance with the observed Ex-4-associated control of DNA oxidative 
damage and 4-hydroxy-2-hexenal (a major lipid peroxidation product formed by n-3 polyunsaturated fatty 
acids) levels upon ischemia/reperfusion injury-induced oxidative stress 
227
. 
Autophagy is a catabolic mechanism that, physiologically, contributes for cell survival due to the 
degradation of old and damaged proteins; nevertheless, some controversy exists on the role of autophagy after 
brain damage, as it has also been implicated in cell death 
29
. From our results on the protein expression levels of 
the commonly used autophagic markers LC3-II (expressed in autophagosomes 
48
), beclin-1 and PI3K class III 
(both regulatory proteins that form an initiator complex in the autophagic process 
28,49
), as well as from the 
phospho-mTOR/mTOR (a key regulator of autophagy), we could infer that the autophagic process could be (at 
least partially) more activated in brain cortices from the Ex-4-treated GK rats and, thereby, constituting a 
protective strategy against T2D-related brain degeneration and death. 
Ex-4 has been shown not only to protect pancreatic -cells against apoptosis, but also to increase their mass 
213,220
. Interestingly and partially in line with a possible induction of a “protective” autophagy by Ex-4 are our 
observations of a tendentially lower activation of the initiator caspases-1 and -2 (belonging to the intrinsic 
pathway) in GK treated rat brain cortices which, together with their tendency to retain the anti-apoptotic Bcl2 
56 
 
and the proapoptotic cytochrome c within mitochondria (whereas the “inactive” proapoptotic Bax remained in 
the cytosol), as in physiological conditions 
67,80,81
, might have contributed for the lower caspase-3 activation 
(the major effector caspase) reported in Ex-4-treated GK rats. Notably, one possible explanation for the 
apparent Ex-4’s efficacy only in the later (rather also in the initial) stages of the apoptotic cascade relied on a 
“controlled”, physiologically-like activation of autophagy in our rodent models. Indeed, Hou et al. (2010) 228 
observed a simultaneous in vitro co-localization of the LC3-II punctuates with processed fragments resulting 
from caspase-8 activation in an HCT116 cell line of human colon carcinoma). This suggested that a similar 
degradation mechanism could be responsible for LC3 and cleaved caspase 8 and, in the presence of lysosomal 
degradation inhibitors, the expression levels of both cleaved caspase-8 and/or punctuate LC3 were maintained 
228
. Therefore, it was possible that, in our conditions, the cleaved caspase-8 was engulfed by the 
autophagolysosomes upon Ex-4 treatment and, thus, we could not observe any direct effect of the drug on 
caspase-8 activation. To our knowledge, despite no further information on a similar effect on other caspases, we 
cannot rule out that Ex-4 activated autophagy may (at least partially) eliminate some of the initial activated 
caspases, thereby interfering with the progression of the apoptotic cascade in GK rat brains. Importantly, these 
results appear to be in accordance with the previously described neuroprotection conferred by Ex-4 against 
apoptosis 
206,229,230
. Although the endoplasmic reticulum-related caspase-12 has been increasingly suggested to 
play a role in AD-associated apoptosis 
97
, it seems unlikely to play a role in our conditions. Additionally, our 
results on necrotic cell death further suggest that necrosis may not underlie T2D-associated brain cortical 
damage, as given by the protein expression levels of RIP1 and RIP3 (two key regulator proteins of necrosis 
104
).  
T2D has been also described to negatively affect brain synaptic function 
124,210
. Accordingly, our results 
suggest that Ex-4 was able to (partially) restore brain cortical synaptic function in T2D GK rats. These results 
were in accordance with the recent observation that Ex-4 promoted LTP, formation of memory and learning 
skills, as well as to restore and enhance cognition in AD patients 
231
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Conclusion 
In the present study, we hypothesized that Ex-4 restores the T2D-associated alterations in intracellular 
quality control mechanisms, neurodegeneration and death, thus improving synaptic function and, ultimately, 
cognitive function. From the previously described results, we can conclude that chronic peripheral 
administration of Ex-4 ameliorated the main pathological features of T2D: hyperglycemia, glucose-intolerant 
and insulin resistant profiles in middle-aged T2D male GK rats.  
Regarding the effect of peripheral Ex-4 administration in GK rat brain cortex, it is possible that the 
restoration of GLP-1 levels might be accompanied by an improvement in GLP-1R activity in brain. However, 
this deserves further clarification. Conversely, as Ex-4 did not interfere with brain cortical insulin levels or its 
receptor activation, it is likely that the subsequent effects of Ex-4 in GK rat brain might not involve insulin/IR. 
Such Ex-4 effects included a restoration of brain glucose levels, a tendency to protect against lipid and DNA 
oxidation and to activate the autophagic process, probably as a protective strategy against the subsequently 
reported T2D-related caspase-3-mediated death in placebo-treated GK rats. Hopefully, this would culminate in 
a slightly improved brain cortical synaptic function in Ex-4-exposed T2D rats. 
Overall, from our results we can conclude that chronic, continuous, peripheral Ex-4 exposure may have 
a beneficial neuroprotective impact in middle-aged, non-obese T2D GK rat brain cortices, thus constituting a 
protective strategy against T2D-related brain degeneration and death. 
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